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CHAPTER I 
INTRODUCTION 
Since the inception of nanotechnology in the 1980s, nanoparticles (NP) have been explored as 
more efficient and less toxic drug delivery systems (DDS). Many of these approaches have used 
organic polymers as their core structures such as cyclodextrin nanosponges (Torne, Darandale, 
Vavia, Trotta & Cavalli, 2013) and biodegradable polymers (Vila, Sánchez, Tobío, Calvo & 
Alonso, 2002) while others synthesized homologs of naturally occurring molecules such as 
liposomes (Batist et al., 2001) and self-assembling peptides (Boopathy & Davis, 2014). Another 
group of NPs have used protein cores around which to build their DDSs. Perhaps the most 
intriguing are albumin-based NPs. 
Albumin provides an excellent core around which to design a DDS. It is biodegradable, 
nontoxic, and easily customizable due to a large number of accessible functional groups on its 
surface. More importantly, albumin is a natural mode of transport for both endogenous and 
exogenous hydrophobic molecules (Elsadek & Kratz, 2012; Elzoghby, Samy & Elgindy, 2012; 
Kratz, 2008; Peters, 1996). 
Albumin-Based Nanoparticles 
 Several approaches have successfully produced nano-scale albumin-based DDSs. 
Discussed below are just a few to demonstrate the breadth of methodologies developed. 
 Desolvation, developed by the Langer group, uses organic solvents such as ethanol and 
acetone to dehydrate drug-loaded albumins. Sedimented protein is polymerized via a cross-  
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linking agent such as glutaraldehyde to provide stability before re-hydration (Langer et al., 2008; 
Weber, Coester, Kreuter & Langer, 2000). Human serum albumin (HSA) NPs were prepared 
using desolvation techniques and loaded with the chemotherapeutic doxorubicin. The NPs were 
further modified by the addition of trastuzumab as a targeting mechanism. Targeted NPs showed 
a cell viability of 20.1%, suggesting successful uptake and drug release (Anhorn, Wagner, 
Kreuter, Langer & von Briesen, 2008). 
 Spray-drying is accomplished by passing a protein solution through a wire mesh at 
elevated temperatures to generate a powder. Smooth, spherical bovine serum albumin (BSA) 
NPs were successfully prepared at temperatures between 80-120oC in the presence of 
Tween®-80. The morphology of the NPs was dependent on the surfactant content. Tween-80, 
often used as an excipient in protein formulations, produced the most homogenous and spherical 
NPs. NP size was most dependent on mesh size. The particle size increased as mesh size 
increased. A 4.0 µm mesh generated NPs 733 nm in diameter while those from a 7.0 µm mesh 
were 2609 nm (Lee, Heng, Ng, Chan & Tan, 2011). 
 Thermal gelation can be viewed as a two-phase process. Albumins are thermally 
denatured and then non-covalently linked via electrostatic and hydrophobic/hydrophilic 
interactions (Boye, Alli & Ismail, 1996). This process was successfully applied to the loading of 
BSA-dextran and BSA-dextran-chitosan NPs with doxorubicin. Covalent BSA-dextran 
conjugates were held at 80oC in the presence of chitosan. The resulting NPs consisted of chitosan 
and dextran arms stretching out from an albumin core. Administration of doxorubicin-loaded 
NPs to cancerous mice showed an increased survivability rate as compared to free doxorubicin 
indicating an increased cell permeability for the conjugate (Qi, Yao, He, Yu & Huang, 2010). 
Each of these systems has a distinct advantage in that they each provide a degree of fine control 
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over the final particle size via alteration of easily monitored parameters (pH, reaction time, 
solvent content, reagent concentration, equipment used). 
The drawbacks of each approach provide cause for concern. Reliance on organic solvents 
and surfactants in the production of materials to be administered to living beings must be 
minimized to avoid toxicity. Thermal denaturation and a highly-altered surface from extensive 
cross-linking may elicit an immune response as well as potentially alter biological activity. 
Necessarily high temperatures place limitations on potential drug candidates. 
nabTM Technology and Abraxane® 
Abraxane®, a paclitaxel (PTX) formulation, is the most successful albumin-based NPs to 
date. Approved in 2005 by the US Food and Drug Administration for the treatment of metastatic 
breast cancer, it is recognized as the first protein-based NP on the market. American Biosciences, 
Inc., now Celgene Corporation, developed a method for producing nanoparticle albumin-based 
(nabTM) carriers of which Abraxane was the first application (Desai, 2008).  
The passage of an aqueous stream of HSA and hydrophobic drug through a high-pressure 
jet forms the nab NP. Albumins adsorb to one another to which drugs preferentially bind. Upon 
administration, the 130-nm shell dissociates (Elsadek & Kratz, 2012; Elzoghby et al., 2012; 
Kratz, 2008).  
Abraxane is the trade name for the complexation of PTX and nab albumin. This product 
was developed as a response to the problems associated with Taxol®, the original formulation for 
stand-alone PTX. In the absence of nab, PTX requires Cremophor® EL (CrEL), a poly-
ethoxylated castor oil, for solubilization. This necessitates infusion times of up to three hours and 
pre-medication with corticosteroids and antihistamines to reduce the chance of hypersensitivity 
reactions. Additionally, PTX delivery was hindered by micellular CrEL formation. Upon 
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administration of Taxol, CrEL aggregates, creating a hydrophobic environment into which PTX 
readily diffuses. CrEL toxicity can be quite severe as it presents as neutropenia and sometimes 
permanent neuropathy (Hawkins, Soon-Shiong & Desai, 2008).  
 The much simpler formulation of Abraxane, consisting of only HSA and PTX, allows for 
shorter infusion times (30 minutes), no pre-medicating, a reduced risk of hypersensitivity 
reactions, and no toxicity (Hawkins et al., 2008). Studies have reported 33% increase of 
intracellular PTX concentrations with Abraxane (Gradishar et al., 2005). Dissociation of 
Abraxane upon administration results in accumulation of albumins into tumor cells via both the 
passive targeting phenomenon of the enhanced permeation and retention effect and active 
targeting via albondin (gp60) endocytosis. It was determined that cancerous cells are able to 
acquire up to 17% of a single dose of 111In-labeled albumin, indicating a degree of preference by 
tumors for albumin (Stehle et al., 1999). By combining albumin’s two-fold tumor targeting with 
the ability of Abraxane to house multiple PTX, an increased drug concentration was 
unsurprising. 
This same housing ability allows for Abraxane to be administered at a 50% higher dose 
than Taxol. PTX introduced into the bloodstream via the Taxol is unbound and free to interact 
with both cancerous and healthy tissues. nab technology provides a means of sequestering the 
chemotherapeutic until it is inside its intended target. This sequestration results in decreased 
toxicity, higher dosage rates, and a higher therapeutic window for Abraxane. 
The wider application of nab technology is questionable. It has proven to be an effective 
chemotherapy due to its high drug load, solubility, and improved administration. The gp60 
targeting mechanism is not universal for all drugs and the dissolution of Abraxane would require 
a targeting mechanism for each individual protein to be as effective for non-chemotherapeutics. 
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Additionally, dissolution of the nab NPs in the bloodstream results in the infusion of a large 
quantity of individual albumin molecules which may greatly impact the osmotic pressure. 
Albumin-Drug Conjugates 
The techniques described result in polymerized albumins which provide a framework to 
which the drug is non-covalently attached. Albumin-drug conjugates remain monomeric and 
provide a means of solubilizing and increasing circulation time for bound ligands. Two 
approaches have been employed to produce these conjugates. In the first, a drug is covalently 
attached to albumin via a surface residue. In the second, the drug is covalently attached to a 
ligand of albumin. Upon administration of this complex, the ligand binds to a high affinity site of 
endogenous albumin, effectively non-covalently binding the drug. 
The first albumin-drug conjugate to reach phase I/II clinical studies was a complex with 
the antimitotic cancer drug methotrexate. Similar to PTX, methotrexate suffered from poor 
solubility and severe toxicity associated with the drug itself and components of the formulation. 
For the conjugate, methotrexate was covalently attached to HSA via lysine residues (Stehle, 
Sinn, Wunder, Schrenk, Schütt et al., 1997). Clinical results for this complex were somewhat 
promising in that three out of 17 patients showed a positive response to therapy. Other factors, 
such as stomatitis, limited the dosage rates, and potentially limited the efficacy of treatment 
(Kratz, 2008).  
Long-lasting insulin (Levemir®) for the treatment of both type 1 and type 2 diabetes is a 
prime example of the second type of albumin-drug conjugate. Novo Nordisk, Inc. developed a 
method for producing recombinant human insulin in which the C-terminus had been shortened 
by elimination of the B-chain terminal threonine. This excision allowed access to an adjacent 
lysine which was covalently attached to myristic acid. Upon administration, the insulin-myristic 
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acid conjugate binds to albumin, resulting in an increase in circulatory half-life from four to six 
minutes for native recombinant insulin to five to seven hours for the conjugate (Elsadek & Kratz, 
2012; Keating, 2012).  
Albumin-drug conjugates are attractive in their reasonably simple production protocols, 
requiring no modifications of the protein outside of the attachment of the drug. While attachment 
to the albumin provides an answer for solubilization, it does not necessarily protect the ligand 
from the host. In the event of an immune response, the drug is susceptible to attack from 
immunogenic agents which could result in early elimination, degradation of the therapeutic, or 
dissection of the conjugate. If the drug were to be cleaved from the albumin before it reaches the 
site of action, a potentially toxic molecule would be released into the bloodstream to interact 
with healthy tissues. 
Serum Albumin 
Physiology 
The robust nature of albumin, a highly-conserved protein found in the serum of all 
mammals, has singled it out as a potential DDS component. It is a 66 kDa monomer produced by 
the liver in quantities up to 12 g/day with a circulatory half-life of 20 days. Albumin can be found 
in high quantities in skin, muscle, liver, and the gut as well as almost all bodily fluids (Lundblad, 
2012; Peters, 1996). Its high production rate and long half-life make albumin the most abundant 
protein in the serum. 
Albumin is able to play a diverse set of roles in the body. Arguably its most important 
function, albumin is the body’s main control on osmotic pressure (Table 1). Determined by the 
number of particles in a system, not their size, osmotic pressure is the driving force between 
  7	
	
tissues and blood. Despite albumin being many times smaller than fibrinogen, it is found at such 
a high concentration that it accounts for 79% of the osmotic pressure (Guyton & Hall, 2006).  
Table 1. Contribution of the Major Classes of Serum Proteins to Osmotic Pressure (Guyton & 
Hall, 2006). 
	
Protein 
Class 
Average 
MW 
 (kDa) 
Serum 
Concentration 
(mM) 
Osmotic 
Pressure 
(mm Hg) 
% Total 
Osmotic 
Pressure 
Albumin 66 0.68 21.8 79 
Globulins 140 0.17 6 20 
Fibrinogen 400 0.0075 0.2 1 
 
 This dependence on albumin as an osmotic regulator must be taken into account when 
designing a DDS. A drastic increase in albumin concentration associated with a high dose of 
albumin-bound drug would be accompanied by a drastic increase in osmotic pressure. This spike 
would cause down-regulation of albumin gene-expression to compensate (Pietrangelo, Panduro, 
Chowdhury & Shafritz, 1992). Decreased levels of native, unmodified albumin may lead to a 
build-up of fatty acids, heavy metals, drugs, and their metabolites. 
Clinical Applications 
 Albumin was first explored as a therapeutic agent during World War II. Albumin 
solutions were administered as plasma expanders to wounded soldiers to minimize the effects of 
blood loss on the battlefield. The first purification method involved multiple rounds of low-
temperature precipitations with ethanol to separate the protein components of blood. Albumin 
was the fifth precipitate in the process and was originally deemed “Cohn Fraction V” (Cohn et 
al., 1946; Peters, 1996). The peptide sequence of BSA was first published by Brown (1975) 
while that of HSA was later independently reported by the Brown and Kostka labs (Behrens, 
Spiekerman & Brown, 1975; Meloun, Morávek & Kostka, 1975). Since these initial works, 
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albumin has become a staple of hospitals and clinics. Unmodified albumin is still used as a 
plasma expander to aid in post-operative recovery and for treatment of shock and burns. It is also 
used to treat patients suffering from hypoalbuminemia, specifically those with acute liver failure. 
In these cases, the liver is unable to produce the requisite amount of albumin and the body 
requires supplementation to maintain normal functionality (Lundblad, 2012). It has also been 
developed as a protein-based resin for sealing wounds by CryoLife, Inc. BioGlue® contains 
compartments of aqueous glutaraldehyde and BSA solutions. These are mixed in the syringe tip 
during application and allowed to bond in situ. The resin is a matrix of highly cross-linked 
albumin strong enough to hold tissues together during the healing process and safe enough to be 
used internally ("CryoLife: BioGlue Instructions for Use," 2017). 
Structural Basis for Ligand Binding 
Albumins contain approximately 585 amino acids arranged in a highly helical heart-
shaped tertiary structure (Figure 1). Three similar domains (I, II, and III) are each subdivided 
into subdomains A and B. Each domain is composed of 10 helices with six in subdomain A and 
four in subdomain B. Each subdomain is connected by a long loop. Conformational flexibility is 
conferred by helical bending and subdomain orientation is controlled by the movement of the 
loops. These types of movements open and close the various binding sites dotted throughout the 
structure. 
While albumin is extremely flexible, the core structure is maintained via 17 disulfide 
bridges. Subdomain A is stapled together by four of these while two bridges stabilize subdomain 
B. The sole exception is Subdomain IA, which contains only three cystine bridges (Bujacz, 
2012). 
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Figure 1. Crystal structure of human serum albumin. (a) Space-filling model and (b) Ribbon 
structure highlighting the three domains and heart-shaped structure. Domains I (blue), II 
(yellow), and III (red) are held together by 17 disulfide bridges (gray). PDB ID: 1E7I 
(Bhattacharya, Grüne & Curry, 2000). All crystal structure images were prepared using UCSF 
Chimera (Pettersen et al., 2004) and rendered with POV-Ray ("Persistence of Vision Pty. 
Ltd.: Persistence of Vision (TM) Raytracer," 2004). 
 
Binding sites. In addition to its role in controlling osmotic pressure, another crucial 
function of albumin is its ability to bind a wide variety of ligands including fatty acids, heavy 
metals, drugs, and drug by-products (Figure 2). Discussed here are just a few of the many 
binding sites on albumin. 
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Figure 2. A selection of albumin binding sites. Fatty Acids are represented as yellow 
hydrophobic tails with red hydrophilic heads. PDB ID: 1E7I (Bhattacharya et al., 2000). 
 
Fatty acid sites. Several sites have been identified for long- and medium-chain fatty acids 
(Ashbrook, Spector & Fletcher, 1972; Ashbrook, Spector, Santos & Fletcher, 1975; Bhattacharya 
et al., 2000). A preference for saturated, long-chain fatty acids was determined by examining 
fatty acid content and association constants. Oleic (18:1, 33%), palmitic (16:0, 25%) and linoleic 
acid (18:2, 20%) made up a majority of the bound fatty acid content of HSA. Five others 
accounted for another 12.5% and ranged between C14-C20 and zero to four degrees of 
unsaturation (A. Saifer & Goldman, 1961). Examining a series of fatty acids ranging from C6-
C18 and zero to two degrees of unsaturation confirmed this preference for saturated, long-chain 
fatty acids. Affinity increased with carbon count and decreased as double bond content increased 
(Spector, 1975). As in the case of Levemir, this binding site allows for tailoring of a drug 
conjugate to take advantage of an innate function of albumin to form a DDS in vivo. The lack of 
modifications to the protein allow it to maintain functionality and avoid degradation.  
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Cys34. A single free thiol found at residue 34 has been reported to participate in covalent 
interactions with a variety of drugs and their metabolites, including bucillamine derivatives 
(Narazaki, Hamada, Harada & Otagiri, 1996), nitrogen mustards (Noort, Hulst & Jansen, 2002), 
and the reactive acetaminophen metabolite, N-acetyl-p-benzoquinoneimine (LeBlanc, Shiao, 
Roy & Sleno, 2014). This residue is on the surface of the molecule, slightly buried in a shallow 
cleft between two α-helices positioned well away from the two main drug binding sites. The 
accessibility of Cys34 provides a great deal of control over conjugation of albumin to other 
molecules. Given that it is the only sulfhydryl available, this allows for chemoselective, covalent 
surface modification. 
The N-terminus and the Multi-metal binding site. Many species of albumin, specifically 
HSA and BSA, employ the X-Y-His motif at the N-terminus (NTS). This configuration allows 
for high affinity binding of Cu(II) on the order of 1 pM (Rózga, Sokołowska, Protas & Bal, 
2007). This strong association between the NTS and Cu(II) must be taken into account during 
DDS development. Cu(I) is a catalyst for a set of biorthogonal reactions involving azides and 
alkynes which will be discussed in more detail in other sections. 
A secondary metal interaction site has been found. Deemed the Multi-metal binding site, 
this area is known to interact with Cu(II), Ni(II), Zn(II), and Cd(II), however, none of these 
species bind with high affinity. Typically, metal cations are not bound until the NTS has been 
fully saturated (Bal, Christodoulou, Sadler & Tucker, 1998). Due to low affinities and little 
impact on the NTS, this site has been largely ignored in favor of a better understanding of the 
high-affinity NTS interaction with Cu(II). 
Drug Site II (DS2). The two main drug binding sites of albumin were initially 
characterized by Sudlow et al. (1975, 1976). One site has been deemed Sudlow Site II or Drug 
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Site II. It is a small, compact single chamber with a patch of polar residues at the entrance to the 
cavity (Figure 3). Tyr411, Arg410 and Ser489 line the mouth of the site, serving as the only 
polar residues in the entire space. 
 
 
Figure 3. Structure of Drug Site II in human serum albumin. Polar residues (green) lining the 
mouth of the cavity are the only polar features of DS2. PDB ID: 2VDB (Lejon, Cramer & 
Nordberg, 2008). 
 
A lack of hydrophilicity in the pocket is mirrored in its ligands which are small 
hydrophobics with a terminal polar group (Table 2) (Yamasaki, Chuang, Maruyama & Otagiri, 
2013). The hydrophilic head, typically a carboxylic acid, is used to anchor the molecule in the 
pocket. This also leads to a high degree of stereospecificity for ligand orientation. By no means a 
flexible site, DS2 has shown the ability to make slight adjustments to accommodate side-chain 
phenyl groups (Ghuman et al., 2005; Yamasaki et al., 2013). 
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Drug Site I (DS1). Drug Site I or Sudlow Site I is a large, multi-chamber, mostly apolar 
pocket with a few polar features that are key to the binding of ligands (Figure 4). A polar 
environment is formed at the entrance to the cavity by Lys195, Lys199, Arg218, and Arg222. 
Three residues are buried deep into the bottom of the site which help to orient molecules 
(Tyr150, His242, Arg257). Ile264 splits the large chamber, giving a total of three subsites for 
binding. Additionally, Trp214 resides near the mouth of the cavity. While this may participate in 
hydrogen bonding with ligands and play a role sterically, it also serves as an innate fluorescent 
probe for studying drug interactions (Ghuman et al., 2005; Yamasaki et al., 2013). 
 
 
Figure 4. Structure of Drug Site I in human serum albumin. Polar residues (pink) at the entrance 
and back (orange) of the cavity are able to hydrogen bond with ligands. Ile264 (purple) divides 
the chamber into smaller subsites. Trp214 (red) provides an intrinsic probe for ligand binding. 
PDB ID: 2VDB (Lejon et al., 2008). 
 
 DS1 has been called a “large and flexible region.” It is able to bind a wide range of 
ligands, often more than one at a time, and is not stereospecific (Kragh-Hansen, 1988). 
Molecules that show a high affinity for DS1 are typically large, flat, and aromatic with at least 
one terminal and one internal polar functional group (Table 2). Flat molecules are preferred for 
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DS1 due to Leu238 and Ala291 which are able to snugly fit the molecule into place. Terminal 
polar moieties are needed to interact with the entryway residues while the internal polar group 
interacts with the buried polar residues (Ghuman et al., 2005; Yamasaki et al., 2013). 
 While each of these sites exhibits preferential binding for certain types of molecules, they 
are by no means exclusive for those molecules. Once the preferred site is filled, additional 
molecules are often able to bind with lower affinities to other sites. In the case of naproxen, 
crystal structures revealed three separate binding sites. DS2 was the preferred site as it was the 
only site consistent between bovine, equine, and leporine serum albumins. Additional naproxen 
were found in a fatty acid site and DS1 (Bujacz, Zielinski & Sekula, 2014).  
Albumin Metabolism 
Albumin has a half-life of 20 days, passing through circulation thousands of times before 
being lysosomally degraded. The pathways used to evade early degradation, delivery of its 
ligand payload, and ultimate catabolism provide useful knowledge for the informed design of 
DDSs. 
The Megalin/Cubilin complexes have been implicated as role players in saving albumin 
from elimination through the kidneys. Cubilin, an extracellular protein, utilizes the 
transmembrane protein megalin to shuttle albumin into the intracellular space. Mice missing one 
or both of these proteins showed decreased albumin reabsorption, strongly suggesting a role in 
albumin recycling (Christensen, Birn, Storm, Weyer & Nielsen, 2012). 
 Similar conclusions were drawn in the case of the neonatal Fc receptor (FcRn). 
Immunoglobulin G (IgG) binds FcRn as a means to cross the placental barrier. Co-elution of the 
IgG-FcRn complex unexpectedly coupled with albumin was the first indication of interaction. 
Studies with FcRn deficient mice found a 40% decrease in albumin serum concentration, owing 
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to the elimination of albumin rather than the transmembrane movement provided by FcRn. 
Under acidic conditions, such as those experienced throughout the lysosomal pathway, FcRn 
binds with high affinity to both albumin and IgG and escorts them to a more neutral environment 
(Kim et al., 2006; Larsen, Kuhlmann, Hvam & Howard, 2016; Merlot, Kalinowski & 
Richardson, 2014). FcRn clearly plays a key role in the long half-life of albumin by way of 
rescuing the protein from degradation. 
Glycoproteins of 30 kDa (gp30) and 18 kDa (gp18) have been shown to play a role in 
albumin catabolism. While native albumin appears able to escape elimination through the 
kidneys via the Megalin/Cubilin complex and FcRn pathways, damaged albumins are tagged by 
gp30 and gp18. The affinities of these proteins for altered albumins are 1000-fold stronger than 
for native albumin. Alterations are often due to oxidative damage or non-enzymatic 
glycosylation. Upon binding, the sequestered albumin is ushered to sites of degradation (Larsen 
et al., 2016; Schnitzer, Sung, Horvat & Bravo, 1992). The albumin is lysosomally catabolized 
and the amino acids re-enter the cycle of protein synthesis (Stehle, Sinn, Wunder, Schrenk, 
Stewart et al., 1997). 
 The most extensively studied albumin receptor is gp60. This receptor is common in 
continuous endothelia from various tissues. It selectively binds albumin and with the help of 
caveolin-1, endocytoses the protein (Schnitzer, 1992). In healthy cells, albumin uses this 
pathway to migrate between the bloodstream and tissue (Merlot et al., 2014). 
 This is not the case in cancerous cells. The fate of albumin and the mechanism of 
chemotherapy release are not fully known. Studies focused on the cellular uptake of Abraxane 
found that the endocytosis of albumin was accompanied by a spike in the concentration of 
osteonectin. It is postulated that osteonectin binds to albumin, tagging it for degradation which 
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releases paclitaxel in the process (Desai, 2008; Hawkins et al., 2008; Tiruppathi, Song, 
Bergenfeldt, Sass & Malik, 1997). 
In addition to gp60 endocytosis, the enhanced permeation and retention effect must be 
taken into account when considering cancerous cells. This is the passive trapping of 
macromolecules in tumor tissues. The cells are growing rapidly and the lymphatic system is 
unable to maintain sufficient drainage which limits the ability of molecules to exit the tumor 
cells. Macromolecules, especially albumins, build up in the cells and are ultimately catabolized 
for protein synthesis and energy. 
Studies have explored the ability of modified albumins to be endocytosed into tumor 
cells. One study covalently attached a low molecular weight protamine fragment to 
chemotherapeutic-loaded BSA NPs to facilitate transfer across the blood-brain barrier (Lin et al., 
2016). Despite the modification, BSA was still successfully taken into tumor cells. 
Both pathways have been exploited as ingress for chemotherapeutics into cancerous 
tissues. The advantages are two-fold. The chance of toxicity due to free ligand is greatly reduced 
when bound to albumin which also provides an innate targeting mechanism. 
Human vs. Bovine Serum Albumin 
 To date, most clinical-use albumin formulations have been HSA-based. However, BSA 
provides an alternative to address many concerns associated with a human blood-borne protein. 
 The main concern with using any human-derived blood product is the possibility of 
disease. Human immunodeficiency virus, Hepatitis, Creutzfeldt-Jakob Disease, and West Nile 
Virus are all potential pathogens that may be transferred with blood products. Despite the 
stringent protocols employed to eliminate and avoid these blood-borne diseases, the stigma of a 
formulation containing a human blood-based protein could decrease patient compliance. 
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Additionally, the supply and cost of HSA is a cause for concern. The two main avenues 
for gathering HSA are donations and recombinant technology. Donation based materials are 
often in limited supply and can cause a fluctuation in availability. Recombinant human albumin 
has been developed with rice (He et al., 2011) and yeast (Recombumin® from Albumedix Ltd.) 
(Bosse et al., 2005). These have shown comparable safety, tolerability, pharmacokinetics, and 
pharmacodynamics to native HSA but are quite expensive. 
 As a by-product of the cattle industry, BSA provides a much more cost-effective and 
readily available substitute for HSA. A BLAST® search shows 76% homology between HSA and 
BSA, suggesting a high degree of structural similarity.  
Amino Acid Correlation 
Comparison of amino acid composition shows strong correlations for key residue types. 
The solubility of albumin is tied to the number of external charged amino acids. Approximately 
31% of the residues on both species are charged, confirming similar solubilities. 
A single free thiol can be found in both albumins. Of the 35 cysteine residues, 34 are 
paired to make disulfide bridges that stabilize the tertiary structure of the three domains. This 
unpaired cysteine allows for more controlled surface modification at a single, specific site. 
Functionalization via surface modifications is a key attractant to albumin as a DDS. 
Lysine residues are often the sites targeted as their terminal amino groups are able to react with a 
variety of functional groups, allowing flexibility in the type of conjugation chemistry used. Both 
species contain 59 lysines, each of which is a potential location to anchor a targeting molecule, 
covalent drug conjugate, cross-linker, or polyethylene glycol chain. 
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Structural Homology of DS1 and DS2 
 A closer look at the Sudlow sites reveals a strong contrast between species. The polar 
residues of DS2 in HSA are present in BSA as residues Tyr410, Arg409, and Ser488 (Figure 5). 
Conservation of the key residues implies similar binding capabilities and preferences for similar 
molecules. 
 
 
Figure 5. Comparison of Drug Site II between human and bovine serum albumin. (a) DS2 of 
HSA. PDB ID: 2VDB (Lejon et al., 2008). (b) DS2 of BSA. PDB ID: 4OR0 (Bujacz et al., 
2014). Polar residues (green) are conserved between species. 
 
As in HSA, DS1 of BSA contains a single tryptophan, Trp213. The polar features buried 
in the cavity of DS1 are consistent between HSA and BSA (Tyr149, His241, and Arg256). Some 
discrepancies are found at the entrance to DS1. The polar cluster of HSA is closely mimicked in 
BSA (Arg194, Arg198, Arg217, and Lys221) (Figure 6). However, the substitution of arginines 
for lysines may cause differences in binding capacities. The distal guanidinium group of arginine 
allows for more hydrogen-bonding and stronger ligand interactions. The delocalized charge, 
however, weakens the bonds with individual molecules (Li, Vorobyov & Allen, 2013). 
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Sterically, the guanidinium R-group is bulkier than the terminal amine of lysine which may 
hinder entry and exit from DS1 in BSA. Despite these discrepancies, interchange of these two 
proteins should be possible. 
 
 
Figure 6. Comparison of Drug Site I between human and bovine serum albumin. (a) DS1 of 
HSA. PDB ID: 2VDB (Lejon et al., 2008). (b) DS1 of BSA. PDB ID:4OR0 (Bujacz et al., 2014). 
External (pink) and internal (orange) polar residues are well-conserved between species. 
Additionally, Trp (red) provides a native fluorophore in both forms of albumin. 
  
Polyethylene Glycol (PEG) 
Polyethylene glycol (PEG), a water-soluble polymer, is used in a wide variety of 
industries for a wide variety of applications from control of the viscosity of printer ink to an anti-
foaming agent in food preparation to laxatives as pre-operative patient preparation. In laboratory 
use, it has been employed as a protein precipitating agent as well as a means to facilitate cell 
fusion (Zalipsky & Harris, 1997). 
PEG is available in a wide range of sizes and functional groups. Entire companies have 
been built around the production and customization of PEGs tailored for specific uses ("Creative 
PEGworks: PEG Products," 2017; "JenKem Technology: PEG Products," 2017). PEGs from as 
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small as 400 Da (PEG400) to as large as 40,000 Da (PEG40k) have been examined as possible 
surfactants and DDS components. 
PEG-Protein Nanoparticles 
PEG has played a role in the development of several successful protein-based NPs (Table 
3) (Haag & Kratz, 2006; "US Food and Drug Administration: Drug Approval Packages," 2017; 
Veronese, Mero & Pasut, 2009). The regulatory approval of the first PEGylated enzymes, 
Adagen® and Oncaspar®, in the 1990s was the turning point for the change of perspective 
towards PEG as a building block for future DDSs rather than a mere additive to formulations 
(Duncan & Veronese, 2009). As a result, more research has been done on the metabolism, 
toxicity, and benefits of PEGylation. 
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PEG Metabolism 
Heavy PEGs (MW > 1000 Da) are minimally absorbed by the gastrointestinal tract. For 
this reason, the oral administration of PEG conjugates is ineffective. The harsh environment of 
the digestive system limits the types of conjugates that can be administered orally. PEG-protein 
complexes risk damage due to enzymatic degradation before entering the bloodstream. For these 
reasons, most PEGylated drugs are administered via injection or intravenously. 
Increasing PEG molecular weight corresponds to an increased circulatory half-life. In a 
study monitoring the distribution of 125I-labeled PEG between MWs of 6,000 Da (PEG6k) and 
190,000 Da (PEG190k), urinary clearance decreased as molecular weight increased. PEG6k had 
a half-life of 18 minutes following intravenous administration. PEG190k, nearly 30 times larger, 
had a half-life of approximately 24 hours (Yamaoka, Tabata & Ikada, 1994). The size of the PEG 
chain clearly has an effect on time retained by the body. 
 Evidence was found that PEG-protein conjugates were first broken down by degradation 
of the protein followed by cleavage from the PEG backbone. Once separated, PEG is passed 
through the kidneys while proteins are catabolized under normal pathways, producing non-toxic 
metabolites (R. Webster et al., 2009). The safety of the remaining PEG must be examined to 
determine the suitability of these conjugates as DDSs. 
Toxicity 
Toxicity has only been associated with extremely low molecular weight PEGs. Fatalities 
have been reported in burn patients after treatment with an antimicrobial cream containing 95% 
PEG300. It was found that in vivo, PEG400 and smaller were oxidized by alcohol dehydrogenase 
into toxic diacid and hydroxyl acid metabolites in the blood, poisoning the patients. The rate of 
oxidation decreased greatly with increased PEG size. The smallest PEG studied, ethylene glycol 
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(MW 62 Da), was degraded 32 times faster than the largest, octaethylene glycol (MW 370 Da) 
(Herold, Keil & Bruns, 1989). Another study administered PEG400 and smaller to mice and rats. 
Doses of 10 mL/kg or less proved fatal (Bartsch, Sponer, Dietmann & Fuchs, 1976). Intravenous 
administration of PEG1400 and larger showed no toxicity or negative effects in rabbits and dogs 
(Working, Newman, Johnson & Cornacoff, 1997). 
Advantages of PEGylation 
As Table 3 details, several proteins have been successfully attached to PEGs of various 
sizes. The benefits of PEGylation are most strongly tied to the hydrophilicity of PEG itself. This 
hydrophilicity, due to the oxygen content of the PEG backbone, means that PEG and its 
conjugates are highly soluble and highly hydrated in aqueous environments. It is estimated that 
PEG is able to adsorb three to five water molecules per ethoxylene subunit, thus greatly 
increasing the hydrodynamic volume of the backbone. Increased hydrodynamic volume results in 
a molecule that appears too large to pass through kidney filtration (Figure 7). Avoidance of 
elimination via normal pathways leads to increased circulatory half-life (Plesner, Fee, Westh & 
Nielsen, 2011; Veronese et al., 2009). 
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Figure 7. Diagram of a PEGylated protein nanoparticle. Covalent conjugation of PEG chains 
onto the surface of a protein greatly increases the hydrodynamic volume of the NP, conferring 
increased circulation lifetime and immunogenic masking. 
 
Avoidance of degradation by immunogenic agents also increases the circulation half-lives 
of these NPs. Chicken Immunoglobulin Y was administered to mice in native and PEGylated 
forms. Protein conjugated with 3-13 PEG5k or PEG20k showed immune response levels drop to 
as low as 1.6% detection (Gefen et al., 2013). PEGylation is able to mask bound protein from 
immunogenic response as the antibodies are unable to sense the protein core due to steric 
hindrance from the PEG backbones. This helps to protect the NP against damage and 
degradation. 
 PEGylation confers a number of benefits to the attached protein core. However, 
PEGylation may also be deleterious to the NP. The attachment of PEG is typically done through 
covalent bonds with surface residues. Eliminating these charges and masking the protein surface 
may lead to poor target and ligand recognition which, in turn, could greatly alter the biological 
activity of the protein. 
 The effects of PEGylation on albumin stability were monitored using PEG chains ranging 
from PEG5k to PEG60k attached to BSA at Cys34 via the thiol-ene reaction. Circular dichroism 
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studies showed no loss of secondary structure after PEGylation. Upon application of heat, it was 
found that attachment of PEG, slightly lowered the temperature of denaturation of 82.5oC for 
unmodified BSA by 2-3oC. There was no direct correlation between the change of denaturation 
temperature and PEG molecular weight. There does, however, appear to be a connection between 
molecular weight and the temperature of aggregation. For PEGs between 10-40 kDa, aggregation 
began at 81oC while unmodified BSA began to aggregate at 71oC (Plesner et al., 2011). It 
appears that the stability of BSA is slightly compromised but the PEG backbone helps to stave 
off aggregation. 
It should be noted that while attaching many strands of small molecular weight PEG has 
been successful, it has been proven to be more beneficial to use less PEGs with a total weight 
equal to these small PEGs. The Williams group demonstrated that attaching two to five strands 
of PEG30k to superoxide dismutase was more effective than 7-15 strands of PEG5k in 
preserving biological activity, increasing lifetime and reducing immunogenicity (M. G. P. Saifer, 
Somack & Williams, 1994). 
“Click” Chemistry 
“Click” chemistry denotes a series of reactions which are modular and give high yields. 
Reaction conditions are simple and insensitive to water and oxygen. The stereospecificity of 
these reactions is what makes them so attractive for bionconjugation. The final product is due 
completely to the functional groups reacted. Groups attached to these reactive moieties may 
enhance the reaction but may not change the final product (Kolb, Finn & Sharpless, 2001). 
 The basis for click chemistry begins with a modification of the Huisgen reaction between 
azides and alkynes. This reaction was largely ignored because of the need for high temperatures 
and pressures. The use of a Cu(I) catalyst as a way to run these reactions under less extreme 
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conditions paved the way for the rapid rise in popularity of click chemistry (Rostovtsev, Green, 
Fokin & Sharpless, 2002; Tornøe, Christensen & Meldal, 2002). These reactions and their 
applications have been extensively reviewed by Kolb et al. (2001) and Thirumurugan et al. 
(2013). 
Azide-Alkyne Cycloaddition (AAC) 
 Cu(I)-catalyzed AAC (CuAAC). The Cu(I)-mediated reaction between azides and 
alkynes (Figure 8) is the prototypical click reaction. It is fast, high-yielding, and stereospecific, 
giving only 1,4-disubstituted 1,2,3-triazoles. Reaction conditions do not require elevated 
temperatures or pressures. 
 
 
Figure 8. Cu(I)-catalyzed azide-alkyne cycloaddition. The reaction of a terminal azide with a 
terminal alkyne in the presence of Cu(I) with a compliment of ligand, reducing agent and 
suppressor reagent results in a single 1,4-disubstituted 1,2,3-triazole product. Kinetics may be 
enhanced by incorporating an electron-withdrawing group at the R3 position. 
 
The employment of a copper catalyst is accompanied by a variety of complimentary 
reagents. The accelerating ligand chelates the copper and helps maintain the proper coordination 
environment. The catalyst is more cost-effective as a Cu(II) salt and reduce which is reduced in 
situ by an agent such as ascorbate. However, this reduction often results in reactive oxygen 
species which may modify amino acid side chains. To counteract this, aminoguanidine is 
included (Hong, Presolski, Ma & Finn, 2009). 
Despite the high solubility and stability of these reagents at physiological pH, this form 
of AAC is not ideal for production of albumin-based DDSs. As previously discussed, the N-
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terminus in many albumins is able to bind Cu(II) with an affinity of 1 pM. The bound Cu(II) will 
be difficult to remove during work-up of the resulting NPs. All traces of copper must be removed 
before introduction into a patient as additional, undesirable heavy metals are toxic to the host. 
Cu(II) has been implicated in neurodegenerative diseases, including prion diseases and 
Alzheimer’s disease (Rózga et al., 2007). While the copper catalyst and its compliment of 
reagents are readily available and cost-effective, simpler AAC reactions have been developed. 
 Strain-promoted AAC (SPAAC). Copper-free click chemistry circumvents the need for 
a Cu(I) catalyst by incorporating the alkyne into a strained ring such as a cyclooctyne or 
cyclononyne (Figure 9a) (Agard, Prescher & Bertozzi, 2004). With a simple, unsubstituted 
cyclooctyne, the reaction kinetics are considerably slower than those of CuAAC. Attachment of 
electron withdrawing groups onto the ring adjacent to the alkyne has been used to increase 
reaction rates. Difluoro- (Figure 9b) and Dibenzocyclooctynes (Figure 9c) returned rates back to 
those of CuAAC without the need for a Cu(I) catalyst and have become the first choice for 
SPAAC reactions (Ning, Guo, Wolfert & Boons, 2008; van Berkel et al., 2007). 
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Figure 9. Strain-promoted azide-alkyne cycloaddition. (a) By incorporating the alkyne into a 
strained ring system, the reaction with a terminal azide no longer requires a catalyst or the 
compliment of reagents needed for CuAAC. The same 1,4-disubstituted 1,2,3-triazole product is 
formed but with slower reaction kinetics. (b) Difluoro- and (c) Dibenzocyclooctynes have been 
shown to increase the kinetics to rates comparable to CuAAC (Ning et al., 2008; van Berkel et 
al., 2007). 
 
Azides and alkynes are biorthogonal as both are virtually absent from nature. The sole 
exceptions are azide-containing natural products found in toxic red algae on the Gulf Coast of 
Florida. Additionally, both are virtually non-reactive with any naturally-occurring functional 
group (Baskin & Bertozzi, 2009). This, coupled with the reduced toxicity due to the elimination 
of the copper catalyst, make SPAAC an excellent candidate for conjugation chemistry with 
albumin. 
Thiol-ene Reactions 
Thiol-ene reactions, while involving neither an azide nor an alkyne, are another class of 
click chemistry (Figure 10). All of the criteria are met in that the reaction is simple and the 
product formed is stereospecific and gives high yields (Lowe, 2010). This reaction is especially 
applicable to proteins with exposed cysteine residues. The free thiol may be chemoselectively 
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reacted with an alkene-containing linker to attach drugs or targeting molecules (Chalker, 
Bernardes, Lin & Davis, 2009). 
 
 
Figure 10. Thiol-ene reaction. (a) A thiol from an exposed cysteine may be reacted with an 
alkene resulting in a thioether linkage. (b) A common form of the -ene used in these reactions is 
the maleimide functional group. 
 
The most common functional group employed for protein modification at cysteines is the 
maleimide. Incorporation of the electron-deficient moiety into the molecule to be attached to the 
protein allows for fast and easy modification under physiological conditions. For example, a 
maleimide-methotrexate prodrug was developed as a treatment for arthritis (Fiehn, Kratz, Sass, 
Müller-Ladner & Neumann, 2008). Upon intravenous administration, this prodrug binds to 
Cys34 of HSA in vivo. The conjugate is later enzymatically cleaved, releasing a bioactive 
derivative of methotrexate. The maleimide-cysteine reaction is rapid and selective, greatly 
increasing the efficacy of the methotrexate treatment. 
Summary 
BSA provides an intriguing option to build a nano-scale DDS. It is highly soluble, with a 
plethora of binding pockets, and a large number of surface residues which can be used for 
customization without the need for recombinant methodologies. Its structural similarities with 
HSA suggests a similar degree of effectiveness can be achieved when incorporated into any of 
the published NP methodologies. 
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A multitude of approaches have been attempted at formulating a successful albumin-
based DDS. Each was successful at solubilizing a hydrophobic pharmaceutical in the presence of 
albumin but flaws in each must be addressed to move forward. Only one albumin-based NP has 
successfully made it to market. Abraxane, while effective, still requires an infusion of a large 
dose of albumin into the bloodstream, potentially affecting the osmotic pressure and 
subsequently the production of native albumin. 
Several PEGylated proteins have been approved, but none are DDSs. PEGylation has 
proven to be advantageous as it confers increased hydrodynamic volume which leads to 
increased circulation lifetimes and decreased immune response. However, PEGylation may 
slightly destabilize the protein at elevated temperatures and steric hindrance due to the attached 
PEGs may negatively affect biological activity and cellular recognition. 
The biorthogonality of SPAAC and the selectivity of the thiol-ene reactions allow for 
easy modification of surface residues of BSA. Due to the high affinity between the N-terminus of 
albumins and Cu(II), traditional CuAAC cannot be used. A strained cyclooctyne further modified 
by an electron-withdrawing group provides an even easier and simpler alternative. 
A NP that can successfully harness the advantages of albumin, avoid the pitfalls 
encountered in other production methods, and gain the advantages of PEGylation with simple 
surface modifications would prove beneficial for the advancement of nanotechnology as DDSs. 
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CHAPTER II 
STATEMENT OF RESEARCH 
The aim of this research is to develop a multi-use albumin-based nanoparticle for drug delivery 
in order to address the concerns associated with current methodologies and available products. 
The most pressing concerns are the cost and risk of pathogens associated with human-sourced 
blood proteins, the negative effect on osmotic pressure due to a large dose of albumins, the 
potential immune response and loss of biological activity due to heavy modification of these 
albumins, and the need for organic solvents for preparation of these products. 
 Most market available albumin formulations use human serum albumin. When sourced 
from blood donations, supplies are limited and the risk of potential contamination with pathogens 
such as human immunodeficiency virus and hepatitis must be considered. Recombinant albumin 
provides a reliable but expensive way to avoid these human pathogens. An alternative approach 
is to use bovine serum albumin (BSA). This species of albumin is cheaper and more readily 
available than its human counterpart. The two are structurally similar. Specifically, key residues 
of Drug Sites 1 and 2 are conserved, suggesting similar binding capabilities. 
Covalent attachment of polyethylene glycol (PEG) chains to proteins has been shown to 
greatly increase circulatory half-life and reduce immunogenic response. In this research, several 
BSAs will be attached to an 8-arm polyethylene glycol backbone (BSAx-R-PEG8) using two 
types of reactions, resulting in different “R” group linkers between protein and backbone. Use of 
a branched PEG backbone minimizes the effect on osmotic pressure. Upon administration of a  
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single dose of drug, the total number of albumins introduced into the bloodstream will be greatly 
reduced with BSAx-R-PEG8 as opposed to conventional albumin nanoparticles. 
 In the first part of this work, the lone, unpaired sulfhydryl of BSA at Cys34 will be 
reacted with a maleimido-functionalized PEG8 (Mal-PEG8) resulting in a thioether (te) linkage. 
This eliminates the need for organic solvents entirely, requires no additional modifications to the 
protein and provides a chemoselective conjugation method. Yields, secondary structure, 
speciation, and ligand binding capabilities will be determined for this form of PEGylated BSA 
(BSAx-te-PEG8). 
 Secondly, BSAx-R-PEG8 will be prepared using strain-promoted azide-alkyne 
cycloaddition. BSA, “activated” at a single superficial lysine with either a short- or long-chain 
Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DIBO-NHS; DIBO-PEG4-NHS), will be 
PEGylated via reaction with complimentary terminal azides (N3-PEG8). BSA and PEG8 will be 
conjugated via a 1,2,3-triazole (123t). This approach requires a single modification of the 
albumin and a minimal amount of organic solvent necessary to dissolve each activating agent. 
PEGylated BSA activated with the short alkyne (BSAx-123t-PEG8) will be used to optimize the 
PEGylation methodology. BSAx-123t-PEG8 and PEGylated BSA activated with the longer 
alkyne (BSAx-PEG4-123t-PEG8) will be characterized in terms of secondary structure, 
speciation, and ligand-binding capabilities. 
 The third area of research examines the effect of these methods of PEGylation on the 
stability of BSA. Monitoring the temperatures of denaturation and aggregation of PEGylated 
BSA has shown a reduction in thermal stability of the attached protein. Published works have 
examined complexes containing a single albumin conjugated with multiple PEG backbones, 
resulting in a higher degree of modification. These complexes showed a slight decrease in the 
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temperature of denaturation is accompanied by an increase in the temperature of aggregation. 
BSAx-te-PEG8, BSAx-123t-PEG8, and BSAx-PEG4-123t-PEG8 complexes require a single point 
of modification in order to attach multiple albumins to a single PEG backbone. Less 
modification of albumin may have less effect on the thermal stability of the final product. 
 Traditional pasteurization of albumin requires N-acetyl-L-tryptophan and sodium 
caprylate to stabilize the protein during the heating process. Both of these additives have shown a 
preference for DS2, creating competition for potential ligands. In an effort to eliminate these 
stabilizers, PEGylated BSA will be pasteurized in the absence of both reagents. The effects of 
pasteurization on the helicity and ligand binding capabilities of PEGylation by both thiol-
maleimide and strain-promoted azide-alkyne cycloaddition reactions in conjunction with the pre-
loading of a DS2 ligand will be monitored. 
Every drug delivery system must be non-toxic, non-immunogenic, cost-effective, easy to 
produce, and applicable to a variety of ligands. By addressing the concerns associated with 
previous approaches, these qualities can be achieved. 
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CHAPTER III 
MODIFICATION OF BOVINE SERUM ALBUMIN WITH 
MAL-PEG8 AS A DRUG DELIVERY SYSTEM  
Introduction 
Serum albumin has become an attractive option in the development of drug delivery systems 
largely due to its role as a vehicle for hydrophobic molecules. Human serum albumin (HSA) has 
been studied extensively for this purpose but the cost of production and risk of pathogenic 
transfer are considerable. Bovine serum albumin (BSA) provides a more cost-effective and 
readily available alternative while maintaining key structural features, including two drug 
binding sites, DS1 and DS2. 
Crystallographic data has shown that DS1 and DS2 are well-conserved between HSA and 
BSA (Bujacz, Zielinski & Sekula, 2014; Lejon, Cramer & Nordberg, 2008). The polar 
environment at the mouth of DS1 is the sole difference between binding sites of these species. In 
HSA, the polar cluster consists of residues K195, K199, R218, and R222 while in BSA, the 
entrance is coated in mostly arginines (R194, R198, R217, and K221). Arginine, while still 
capable of hydrogen-bonding, has a more dispersed positive charge and a larger functional 
group. Sterics as well as the delocalization of the positive charge weaken interactions with 
individual polar molecules (Li, Vorobyov & Allen, 2013). Despite this difference, it is believed 
that DS1 and DS2 on BSA will house similar molecules as HSA. 
A single, free cysteine at position 34 is also conserved across species. In the body, Cys34   
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plays a key role as an antioxidant (Anraku, Chuang, Maruyama & Otagiri, 2013; Roche, 
Rondeau, Singh, Tarnus & Bourdon, 2008) and is also capable of binding various ligands 
(LeBlanc, Shiao, Roy & Sleno, 2014; Narazaki, Hamada, Harada & Otagiri, 1996; Noort, Hulst 
& Jansen, 2002). In terms of drug delivery system development, the most attractive aspect of 
Cys34 is that it provides an accessible, chemoselective site for surface modification. 
Cysteine has been selectively modified using a variety of chemistries (Abbas, Xing & 
Loh, 2014; Abegg et al., 2015; Mehtala, Kulczar, Lavan, Knipp & Wei, 2015) in order to 
increase the circulatory half-lives of a variety of protein-based therapies (Léger et al., 2004; 
Plesner, Fee, Westh & Nielsen, 2011; Stoddart et al., 2008). CJC-1134-PC is an application of 
ConjuChem’s Preformed Conjugate-Drug Affinity Complex (PC-DACTM) technology for the 
treatment of type 2 diabetes. This complex consists of maleimido-functionalized Exendin-4, a 
homolog of glucagon-like peptide 1, covalently attached to recombinant human albumin via 
interaction with Cys34. Exendin-4 has a short half-life, requiring twice daily injections to 
maintain therapeutic levels. Conjugation onto albumin extends circulatory lifetime while 
maintaining biological potency (Baggio, Huang, Cao & Drucker, 2008). 
In the case of PC-DAC, the therapeutic agent is left exposed to the environment in order 
to interact with cell surface targets. However, drug molecules need to be removed from the 
environment. Direct conjugation of a drug to Cys34 provides no protection for the ligand, 
subjecting the bound drug to possible degradation or alteration. The binding pockets of albumin 
provide shelter for these molecules while keeping Cys34 free for surface modifications. 
Cys34 is found in a shallow cleft at the surface of albumin in Domain IA (Figure 11). 
DS2, found entirely in Domain IIIA, is likely unaffected by conjugation at a single residue in 
Domain I. DS1, however, is found at the interface of Domains IB and IIA. Modification at Cys34 
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may cause conformational changes which may alter the binding characteristics of DS1.  
 
 
Figure 11. Cys34, Drug Site I, and Drug Site II of bovine serum albumin. (a) Cys34 (brown) is 
located in Domain I (blue), adjacent to DS1 (pink) in Domain II (yellow). DS2 (green) in 
Domain III (red) is far removed from Cys34. (b) It is slightly buried in a shallow cleft on the 
surface of the protein. PDB ID: 4OR0 (Bujacz et al., 2014). All crystal structure images were 
prepared using UCSF Chimera (Pettersen et al., 2004) and rendered with POV-Ray ("Persistence 
of Vision Pty. Ltd.: Persistence of Vision (TM) Raytracer," 2004). 
 
 A common modification for protein-based drug delivery systems is covalent attachment 
of a polyethylene glycol (PEG) backbone. PEG-protein conjugates often consist of multiple PEG 
chains covalently attached at several locations on the surface of a single protein core (Nischan & 
Hackenberger, 2014; Veronese & Pasut, 2005). This approach results in a potential problem for 
albumin-based drug delivery systems. Albumin is a key regulator in osmotic pressure. 
Administration of a large dose of individually PEGylated albumins may lead to down-regulation 
of albumin production (Pietrangelo, Panduro, Chowdhury & Shafritz, 1992). Down-regulation 
would result in accumulation of materials normally transported by albumin, such as toxic 
metabolites and heavy metals. 
 A multi-albumin complex would allow for a higher drug dose with introduction of fewer 
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albumins (Figure 12). Osmotic pressure is controlled by the number of particles, not their 
individual sizes. In the case of serum proteins, with a MW of 400 kDa, fibrinogen is among the 
largest but accounts for only 1% of total osmotic pressure due to low concentration (0.0075 
mM). Albumin, however, is several times smaller (MW 66 kDa) but is found at a much higher 
concentration (0.68 mM) and accounts for 79% of total osmotic pressure (Guyton & Hall, 2006). 
For example, the same therapeutic dose of eight individual albumins pre-loaded with a drug 
could be achieved with administration of a single eight-albumin particle, lessening the effects on 
osmotic pressure of treatment. 
 
 
Figure 12. Diagram of BSAx-te-PEG8. Thioether (te) linkages connect eight BSA molecules to a 
single PEG8 backbone via reaction between terminal maleimides and native Cys34 residues. 
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In this study, BSA will be attached to maleimido-functionalized PEG8 (Mal-PEG8) via 
thiol-ene reaction (Figure 13). A thioether (te) linkage will connect BSA to the PEG8 backbone 
via reaction between a terminal maleimide and native Cys34. The resulting BSAx-te-PEG8 
(Figure 12) will be characterized in terms of yield, secondary structure, speciation, and ligand 
binding. 
 
 
Figure 13. Thiol-maleimide conjugation of bovine serum albumin onto PEG8. The free thiol of 
Cys34 reacts with Mal-PEG8 to give a thioether linkage between protein and PEG backbone. 
 
Materials and Methods 
Materials 
 Lyophilized BSA (Product Number A7906), sulfamethoxazole (SMZ; S7507), naproxen 
(NPX; N8280), and all reagents not detailed were purchased from Sigma-Aldrich.  
Methods 
 All experiments were carried out in 50 mM 4-Morpholinepropanesulfonic acid/0.15 M 
NaCl pH 7.2 (MOPS/NaCl) buffer unless otherwise noted. Fast protein liquid chromatography 
(FPLC) separations were performed on an ÄKTAprime plus chromatography system (Amersham 
Biosciences; 11001313) with MOPS/NaCl mobile phase. Resulting fractions were concentrated 
with 30 kDa MW cut-off centrifuge filters (Sartorius; VS2022). BSA concentrations were 
calculated using absorbance values obtained on an Agilent 8453 UV-visible Spectroscopy 
System at 280 nm with an extinction coefficient of 43.824 mM-1 cm-1 and a MW of 66,430 Da 
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(Hirayama, Akashi, Furuya & Fukuhara, 1990; "Thermo Scientific: Extinction Coefficients," 
2013). 
 Fatty acid removal. Fatty acid-free BSA (FAF-BSA) was prepared via an activated 
charcoal method (Chen, 1967). In short, BSA was dissolved in MOPS/NaCl. The solution was 
acidified to pH 3 and stirred on ice with 20-40 mesh particle size activated charcoal in order to 
remove any bound fatty acids. Charcoal was pelleted at 10,000 rpm and the supernatant was 
filtered through 0.2 µm cellulose filters to remove any remaining carbon. The de-fatted albumin 
solution was returned to pH 7.2 before further purification. Dimers were removed by size 
exclusion chromatography (SEC) on a pre-packed 120 mL 60 cm x 16 mm S300 FPLC column 
(GE Healthcare; 17-1167-01). 
 PEGylation of FAF-BSA. The final product consisted of multiple BSA molecules 
attached to a PEG8 backbone via a thioether (te) linkage formed by the reaction of terminal 
maleimides of PEG8 and the sulfhydryl of Cys34 (BSAx-te-PEG8). 40 kDa Mal-PEG8 (Creative 
PEGworks; PSB-864) was dissolved in MOPS/NaCl and added to 1 mM FAF-BSA at 8:1 FAF-
BSA:Mal-PEG8. The solution was allowed to incubate at room temperature for one week with 
constant stirring. PEGylated FAF-BSA was purified via a two-phase SEC separation. The bulk 
of unreacted FAF-BSA was removed by way of an S300 FPLC column, the remainder via a 320 
mL 60 cm x 26 mm S500 column (GE Healthcare; 28-9356-07). Chromatograms from the S300 
separation were processed in PrimeView 5.0 software to determine yields as the percentage of 
total area count. 
 Circular dichroism (CD). The effects on secondary structure of the PEGylation 
procedure were determined by CD. BSAx-te-PEG8 were assayed in 50 mM MOPS pH 7.2. 
Studies were done on an Olis DSM 20 CD Spectrophotometer. Spectra were collected at 30oC 
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over the range of 190-260 nm with a step-size of 1 nm. Helicity was calculated with DichroWeb 
(Whitmore & Wallace, 2008) and the analysis program CDSSTR (Sreerama & Woody, 2000). 
Inclusion of a crystal structure for HSA (Wardell et al., 2002) allowed for use of reference set 
SP175 (Janes, 2009; Lees, Miles, Wien & Wallace, 2006). 
SDS-PAGE. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed as an initial characterization of BSAx-te-PEG8 species. The assay was performed 
on a PhastSystem (Amersham Biosciences; 18-1018-23) with a 4-15% gradient PhastGel (GE 
Healthcare; 17-0678-01), Coomassie R 350 stain (GE Healthcare; 17-0518-01), and high 
molecular weight markers (GE Healthcare; 17-0615-01).  
 Analytical ultracentrifugation (AUC). AUC was carried out in a Beckman Coulter 
ProteomeLab XL-A analytical ultracentrifuge using standard two sector cells with quartz 
windows in four- or eight-hole rotors. All sedimentation velocity experiments were performed at 
50,000 rpm with a preset scan number of 100 per cell. The reference sector was filled with 450 
µL of MOPS/NaCl and the sample sector was filled with 430 µL of sample with an absorbance at 
280 nm between 0.75 and 1.1. Path length was 1 cm. Buffer density was measured at 20.0oC in a 
Mettler/Paar Calculating Density Meter DMA 55A and the buffer viscosity was measured in an 
Anton Parr AMVn Automated Microviscometer. Data were analyzed using the program Sedfit 
(Schuck, 2000; "Sedfit," 2017). Molecular weights and sedimentation coefficients (S20,w) were 
determined using the continuous c(s) mode in the Sedfit program. Native monomeric BSA 
yielded an S20,w value of 4.04 S which agreed with published values (Shulman, 1953; Taylor, 
1952; Zhao et al., 2015). The c(s) plots were deconvoluted using non-linear least-squares fitting 
algorithms available in the Origin (v. 9.0) software package (OriginLab Corporation, 
Northampton, MA). Data were fit to multiple Gaussian components, increasing the number of 
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components until residual plots (data-fit) were random and the chi square value for the fit was 
minimal. Values reported are percentages of the total area count of peaks corresponding to 
PEGylated species. These area counts were calculated via the trapezoidal formula. 
 Fluorimetric analyses. Binding studies were performed on a Photon Technology 
International fluorimeter using Felix software (version 1.1). SMZ, a DS1 ligand, and NPX, a 
DS2 ligand, were studied to determine if PEGylation affected ligand binding capabilities. The 
number of binding sites (n) and the association constant (Ka) were calculated for BSAx-te-PEG8. 
In each case, the fluorophore monitored was Trp213, found at the entrance to DS1 in Domain 
IIA. 
For SMZ, 30 µM stock solutions of FAF-BSA and BSAx-te-PEG8 were prepared in 0.2 
M Tris-HCl/0.1 M NaCl pH 7.4. SMZ was dissolved in methanol to a final stock concentration 
of 30 mM. Working SMZ stocks were prepared at 3 mM and 1 mM by dilution with Tris buffer. 
Monitoring emission between 300-380 nm upon excitation at 283 nm at 25oC, aliquots of 
working SMZ stocks were titrated into a 3 µM BSA solution. 1 mM working stock was used up 
to 20 µM SMZ. 3 mM working stock was used to raise the final concentration to 80 µM SMZ.  
To determine n and Ka for NPX, 30 µM stock solutions of FAF-BSA and BSAx-te-PEG8 
were prepared in 10 mM phosphate buffer pH 7.0. NPX was dissolved in methanol to a final 
stock concentration of 45 mM. A working NPX stock was prepared at 0.15 mM by dilution with 
phosphate buffer. Monitoring emission between 300-380 nm upon excitation at 295 nm at 25oC, 
aliquots of working NPX stocks were titrated into a 0.725 µM BSA solution to a final 
concentration of 3 µM NPX. 
Blanks for each ligand at each concentration were necessary to account for any 
fluorescence due to the ligand itself. SMZ had almost no signal under experimental conditions. 
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NPX, however, showed strong emission with maxima at approximately 350 nm. Particularly at 
high concentrations, NPX signal obscured the BSA maxima which ranged from 344 to 350 nm. 
Non-linear regression analyses were carried out using The Gnumeric Spreadsheet 
(version 1.10.16) ("The Gnome Project: The Gnumeric Spreadsheet: Free, Fast, Accurate - pick 
any three," 2011) and a modified Hill equation. In order to normalize samples, fractional 
intensities (FrInt) were used in place of raw intensities. 
FrInt	 = 	 FrInt()*	–	FrInt(,- ∗ 	 Ligand -K5- 	+	 Ligand - +	FrInt(,- 
 FrInt	 = 	 (Int,	89	:,;)-5 − Int=	89	:,;)-5)(Int()*	89	:,;)-5 −	 Int=	89	:,;)-5) 
 K) = 1K5 
 
Results and Discussion 
BSAx-te-PEG8 Yield 
BSAx-te-PEG8 was purified via two size exclusion FPLC columns (Figure 14). 
Integration of the S300 separation showed that the PEGylation procedure converted an average 
of 36.1 ± 0.6% of BSA into BSAx-te-PEG8. In the initial purification, a small peak eluted at 
approximately 40 mL suggests the presence of extremely high molecular weight material. This 
same material was buried in the S500 separation, resulting in peak broadening for BSAx-te-PEG8 
fractions. 
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Effects on Secondary Structure 
 Helicity was maintained after the PEGylation procedure. BSAx-te-PEG8 contained 
minima at 210 nm and 220 nm which are characteristic of α-helices (Figure 15). The secondary 
structure of FAF-BSA was 59.2 ± 2.2% α-helical. PEGylation resulted in a slight decrease in 
helicity to 56.3 ± 1.3%. Both values are in agreement with published values which range from 
56-66% helical content for BSA (Das et al., 2017; Moriyama et al., 2008). Given that Cys34 is 
shallowly sheltered in a cleft between two helices, attachment of a large PEG chain may have 
caused some loss of helicity. 
 
 
Figure 15. Circular dichroic spectra of FAF-BSA and BSAx-te-PEG8. FAF-BSA (---) and 
BSAx-te-PEG8 (red) contain minima at 210 nm and 220 nm characteristic of α-helices. 
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BSAx-te-PEG8 Speciation 
Electrophoretic separation of PEGylated BSA via SDS-PAGE revealed the presence of 
high molecular weight material (Figure 16). A faint band at 116 kDa corresponds to dimeric 
BSA and BSA1-te-PEG8 (MW 106 kDa). A second faint band at 170 kDa corresponds to BSA2-
te-PEG8 (MW 172 kDa). A dark streak at MWs heavier than 220 kDa contains distinct banding, 
most likely corresponding to BSA3-4-te-PEG8. Material retained in the stacking zone is made of 
five or more PEGylated BSAs as the molecular weight cut-off for proteins in the separating zone 
is 300 kDa. Smearing is most likely due to interaction of the PEG8 backbone with the 
polyacrylamide gel. 
 
 
Figure 16. Electrophoretic separation of species of bovine serum albumin PEGylated via thiol-
maleimide click chemistry. Lane 1-2: BSAx-te-PEG8; Lane 3: FAF-BSA; Lane 4: High 
molecular weight marker. 
 
  Several species of PEGylated BSA were found via AUC (Figure 17). 70% of the total 
PEGylated area count was due to BSA2-6-te-PEG8. 11% corresponded to a single BSA attached 
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to a single PEG8 backbone. The remaining 19% consisted of very high molecular weight species. 
Given that there are only eight arms on Mal-PEG8 and only one free cysteine on BSA, the largest 
particle, BSA8-te-PEG8, would have a MW of 502 kDa. Peaks with a sedimentation coefficient 
greater than 15 S have calculated molecular weights well above this mark. It is believed that the 
extremely high molecular weight species are a combination of BSA7-8-te-PEG8 and PEGylated 
species of a side-reaction of Mal-PEG8. 
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Peak 1 2 3 4 5 6 7 8 9 10 11 12 
S20,w 2.12 4.24 6.06 7.58 8.79 10.6 12.7 15.8 18.2 19.7 21.8 24.2 
MWcalc 
(kDa) 35 82.7 nr 194 259 343 473 704 nr nr 970 1160 
MWtheor 
(kDa) 66 106 172 238 304 370 436 n/a 
# BSA 
conjugated monomer 1 2 3 4 5 6 n/a 
% Area 
Count n/a 11 9 14 17 15 15 19 
 
Figure 17. Analytical ultracentrifugation analysis of BSAx-te-PEG8. % Area Count values are the 
percent of PEGylated species only. nr: not reported; n/a: not applicable. 
 
 Maleimides react readily with sulfhydryls, however, Mal groups may also react with the 
terminal amino group of lysine (Brewer & Riehm, 1967). At neutral pH, thiolation occurs 1000 
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times faster than the lysine interaction. Given the high concentration of the reaction mixture, the 
large number of superficial lysines, and the long incubation time, it is highly possible that 
multiple lysines reacted with one or more PEG8 chains to create very high molecular weight 
oligomers. 
Results were similar to hemoglobin-based nanoparticles developed with the same Mal-
PEG8 (K. D. Webster et al., 2017). Hemoglobin, a 64 kDa tetrameric protein, contains two free 
cysteines at position 93 of each β-subunit. Similar reaction conditions to those used in this study 
resulted in a heterogeneous mixture of PEG8 complexed with predominantly three hemoglobins. 
As many as six hemoglobin tetramers were found to be conjugated to a single PEG8 backbone. 
BSA, similar in size to hemoglobin, behaved in a similar fashion during PEGylation. A similar 
spread of conjugated protein was found, with a majority of PEGylated species falling between 
two and six BSA molecules per PEG8 backbone. 
Ligand Binding Capabilities 
Fluorescent emission was monitored to determine the viability of DS1 and DS2 of PEG-
conjugated BSA. NPX was used to probe DS2. Published crystal structures of de-fatted bovine, 
equine, and leporine serum albumins complexed with NPX indicate a preference for DS2 
(Bujacz et al., 2014). Experimental values for NPX in the presence of FAF-BSA and BSAx-te-
PEG8 were consistent with published values (Table 4), suggesting that DS2 remains intact upon 
PEGylation. While the crystal structure reported by Bujacz et al. show three NPX molecules 
bound, DS2 has been the only high affinity site reported. Discrepancies in the n values are 
possibly due to de-fatted BSA used in this work while fatty acid-containing albumin was used in 
the published results.  
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Table 4. Association Constants (Ka) and Number of Binding Sites (n) for BSAx-te-PEG8 for 
Sulfamethoxazole and Naproxen. 
 
 SMZ NPX 
Sample Ka (x103 M-1) n Ka (x107 M-1) n 
FAF-BSA 2.03 ± 0.18 0.9 ± 0.1 0.40 ± 0.13 0.4 ± 0.1 
BSAx-te-PEG8 0.19 ± 0.05 0.8 ± 0.03 1.99 ± 0.17 0.9 ± 0.3 
Lit. values1,2 3.55-15.6 0.9-1.0 0.12-3.70 0.6-3 
 
1SMZ values were published by Naik et al. (2009; 2015), Rajendiran & Thulasidhasan (2015), and Wang et al. 
(2014). 
 
2NPX values were reported by Banerjee et al. (2006), Bou-Abdallah et al. (2016), Fielding et al. (2005), and Honoré 
& Brodersen (1984). Bujacz et al. (2014) have reported a crystal structure (PDB ID: 4OR0) for BSA complexed 
with three NPX molecules. 
 
 Binding of NPX to FAF-BSA and BSAx-te-PEG8 showed similar trends (Figure 18). 
BSA in the absence of NPX had a maximum emission wavelength at 344 nm. With increasing 
amounts of NPX, a red shift resulted in a maximum at 350 nm. This is consistent with binding to 
a site adjacent to the fluorophore. In this case, the fluorophore studied was Trp213 found in 
Domain IIA at the mouth of DS1. As ligand binds to DS2, slight conformational changes 
exposed Trp213 to the solvent, causing a red shift. 
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Figure 18. Fluorimetric spectra and non-linear regression of BSAx-te-PEG8 in the presence of 
naproxen. (a) BSAx-te-PEG8 and (b) FAF-BSA spectra. BSA in the absence of NPX (---) had a 
maximum emission at 344 nm. Upon addition of NPX to a final concentration of 3 µM, 
maximum emission shifted to 350 nm and intensities increased. (c) Non-linear regression 
analyses for BSAx-te-PEG8 (red £) and FAF-BSA (black ¯). Experimental data is represented 
as symbols while calculated data points are lines of the same color.  
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DS1, however, appears to be greatly affected by the covalent modification of Cys34. 
FAF-BSA values were similar to published values for both Ka and n for SMZ studies (Table 4). 
However, BSAx-te-PEG8 demonstrated a greatly reduced affinity for SMZ. Spectra for both 
FAF-BSA and BSAx-te-PEG8 followed similar trends (Figure 19). Intensities decreased as SMZ 
concentration increased. The signal from Trp213 is quenched in the presence of the ligand 
though it is not tightly bound in BSAx-te-PEG8. Modification of Cys34 in Domain IA, clearly 
had an effect on binding to DS1 in Domains IB and IIA. 
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Figure 19. Fluorimetric spectra and non-linear regression of BSAx-te-PEG8 in the presence of 
sulfamethoxazole. (a) BSAx-te-PEG8 and (b) FAF-BSA spectra. BSA in the absence of 
SMZ (---) had a maximum emission at 346 nm. Intensities decreased with each addition of SMZ. 
(c) Non-linear regression analyses for BSAx-te-PEG8 (red £) and FAF-BSA (black ¯). 
Experimental data is represented as symbols while calculated data points are lines following the 
same color.   
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Conclusions 
Mal-PEG8 was successfully used as a scaffolding to combine multiple native BSA 
molecules into a single complex with drug binding capabilities. The reaction was simple to run, 
requiring only a relatively high molar ratio of FAF-BSA:Mal-PEG8. A majority of PEGylated 
species contained 2-6 BSA molecules though some species of molecular weights greater than 
BSA8-te-PEG8 were found. While a larger spread of BSAx-te-PEG8 species were generated, the 
complexes still showed the ability to effectively bind drugs to DS2, maintaining the key 
functionality of these albumin-based nanoparticles. 
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CHAPTER IV 
CONJUGATION OF BOVINE SERUM ALBUMIN ONTO PEG8 VIA 
STRAIN-PROMOTED AZIDE-ALKYNE CYCLOADDITION 
AS A DRUG DELIVERY SYSTEM 
Introduction 
The hydrophobicity of many drugs is a major hurdle for efficient delivery to target tissues. Drug 
delivery systems (DDS) aim to increase the bioavailability of pharmaceuticals by increasing the 
solubility and subsequently their efficacy. Increased solubility also reduces the risk of rapid 
elimination and in vivo degradation. 
The ideal DDS must be non-immunogenic, easily eliminated, and applicable to a range of 
drugs. This versatility requires the ability to bind different types of ligands and allow for 
targeting of specific cell types. It must protect the ligand from degradation while protecting the 
host from toxicity by chaperoning bound drug to the site of action. 
Incorporation of serum albumin into a DDS would address many of these points. 
Albumin serves as a natural vehicle for insoluble materials by binding these molecules in a 
variety of hydrophobic pockets found throughout its structure. Albumin-based DDSs have also 
been shown to greatly increase the aqueous solubility of drugs (Khoder et al., 2016). By 
sequestering a pharmaceutical, albumin provides protection against degradation, redox reactions, 
and immunogenic agents. Additionally, the drug is no longer available to freely move through 
the bloodstream and possibly damage healthy tissue, protecting the patient. 
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These hydrophobic cavities are able to non-covalently bind a wide variety of ligands, 
making albumin a versatile drug carrier. Fatty acids (Bhattacharya, Grüne & Curry, 2000), heavy 
metals (Bal, Christodoulou, Sadler & Tucker, 1998; Rózga, Sokołowska, Protas & Bal, 2007), 
and metabolites such as bilirubin (Zunszain, Ghuman, McDonagh & Curry, 2008) are just a few 
of the endogenous materials transported by albumin. The two main binding sites of extrinsic 
hydrophobic molecules are Drug Site I (DS1) and Drug Site II (DS2). Both are mostly apolar 
pockets with only a few hydrophilic residues. DS1, located at the interface between Domains IB 
and IIA, is a large, multi-chambered cavity which is able to accommodate multiple ligands of 
different sizes. DS2, found entirely in Domain IIIA, is less versatile and shows a higher degree 
of stereospecificity due to a much more compact structure. These binding sites are reviewed in 
greater detail by Ghuman et al. (2005) and Yamasaki et al. (2013). 
 Albumin also allows for specific cell targeting. Tumor cells have been shown to 
accumulate albumins passively through the enhanced permeation and retention effect and 
actively via albondin-mediated transcytosis (Desai, 2008; Hawkins, Soon-Shiong & Desai, 2008; 
Tiruppathi, Song, Bergenfeldt, Sass & Malik, 1997). This provides a natural targeting ability for 
chemotherapeutics and led to the approval of Abraxane®, an albumin-based DDS of paclitaxel 
for treatment of metastatic breast cancer (Desai, 2008). 
Additionally, albumins contain up to 59 lysine residues. The terminal amino groups of 
these residues provide a potential site for surface modification with antibodies (Anhorn, Wagner, 
Kreuter, Langer & von Briesen, 2008), vitamins (Leamon & Low, 1991), and other targeting 
molecules. 
One concern for using albumin as a drug-carrier is the effect on osmotic pressure upon 
introduction of a large number of free, individual albumins. Approximately 79% of osmotic 
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pressure is credited to albumin (Guyton & Hall, 2006). For this reason, serum albumin levels are 
tightly regulated by the body. A large infusion of free albumin would be accompanied by down-
regulation of albumin production (Pietrangelo, Panduro, Chowdhury & Shafritz, 1992). This 
would lead to aggregation of fatty acids and other endogenous, insoluble biomaterials in blood 
and tissue. 
Conjugation of multiple bovine serum albumin (BSA) molecules onto a single eight-
armed polyethylene glycol backbone (BSAx-R-123t-PEG8) addresses this concern (Figure 20). 
The linker between PEG8 and BSA in this diagram is a 1,2,3-triazole (123t) formed by strain-
promoted azide-alkyne cycloaddition (SPAAC) with a variable R group spacer between protein 
and alkyne. Osmotic pressure is dependent on the number of molecules present, not their 
individual masses. Delivering the same dose of albumin-drug via BSAx-R-123t-PEG8 would 
have less effect on the osmotic pressure. For example, to deliver therapeutic levels of drug, PEG8 
complexed with eight BSA molecules would require one-eighth of the dose of unmodified 
albumin. Osmotic pressure would be affected by a single molecule as opposed to eight. 
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Figure 20. Diagram of BSAx-R-123t-PEG8. PEGylation run to completion would result in eight 
BSAs attached to a single PEG8 backbone. The linkers between PEG8 and BSA are a 1,2,3-
triazole (123t) formed by SPAAC with a variable R group spacer between protein and alkyne. 
 
PEG is a biologically inert polymer commercially available in a wide variety of sizes and 
functional groups ("Creative PEGworks: PEG Products," 2017; "JenKem Technology: PEG 
Products," 2017). Inclusion of a PEG backbone into a DDS would increase solubility of the 
complex and provide additional protection of the attached BSA molecules from degradation and 
in vivo modifications. 
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Human serum albumin (HSA) has been the main albumin studied for delivery of 
synthetic hydrophobic molecules. HSA, being a human-sourced, blood-borne protein, presents an 
increased risk of pathogen transfer. Recombinant human albumins have been developed but are 
expensive to produce (Bosse et al., 2005; He et al., 2011). BSA provides a readily available and 
inexpensive alternative to its human counterpart. Crystallographic data has shown that many 
structural features, including DS1 and DS2, are well-conserved between HSA and BSA (Bujacz, 
Zielinski & Sekula, 2014; Lejon, Cramer & Nordberg, 2008). The polar environment at the 
mouth of DS1 is the sole difference between binding sites of these species. In HSA, the polar 
cluster consists of residues K195, K199, R218, and R222 while in BSA, the entrance is coated in 
mostly arginines (R194, R198, R217, and K221). While still capable of hydrogen-bonding, 
arginine has a more dispersed positive charge and a larger functional group. Sterics as well as the 
delocalization of the positive charge weaken interactions with individual polar molecules (Li, 
Vorobyov & Allen, 2013). Despite this difference, it is believed that DS1 and DS2 on BSA will 
house similar molecules as HSA. 
While BSA is a natural product that shares a large number of similarities with 
endogenous HSA, BSA is still a foreign molecule and is at risk of being treated as such upon 
administration to humans. Studies have shown that oral and parenteral administration of 
unmodified BSA to humans resulted in production of BSA antibodies. In some cases, no immune 
response was invoked (Korenblat, Rothberg, Minden & Farr, 1968). In cross-species 
administration of proteins, covalently attached PEG has been shown to effectively mask the 
foreign molecules and greatly reduce immunogenic response (Gefen et al., 2013). A PEGylated 
complex such as BSAx-R-123t-PEG8 (Figure 20) may hide the foreign BSA molecules from 
immunogenic agents. 
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 Studies have shown that PEGylated proteins are safely metabolized in two stages. First, 
protein components are degraded. In the case of albumin, glycoproteins gp18 and gp30 bind to 
albumin, tagging it for lysosomal catabolism (Larsen, Kuhlmann, Hvam & Howard, 2016; 
Schnitzer, Sung, Horvat & Bravo, 1992; Stehle, Sinn, Wunder, Schrenk, Stewart et al., 1997). 
The remaining PEG backbone is excreted through the kidneys (R. Webster et al., 2009). Safe 
metabolism is key for any DDS. Once the drug has been delivered, deleterious effects of the 
DDS or its metabolites are undesirable. 
 This BSAx-R-123t-PEG8 complex will be generated using “click” chemistry. The term 
denotes reactions that are modular, able to give near quantitative yields, and are stereospecific. 
These reactions are simple, easy to perform and insensitive to water and oxygen (Lowe, 2010). 
SPAAC is a form of click chemistry in which a terminal azide is reacted with an alkyne 
incorporated into a cyclooctyl or cyclononyl ring. To further strain the already reactive cyclic 
structure, electron-withdrawing groups have been incorporated adjacent to the alkyne in order to 
make it even more reactive with the complimentary azide. The most commonly utilized groups 
are difluoro- and dibenzo- moieties (Ning, Guo, Wolfert & Boons, 2008; van Berkel et al., 
2007). SPAAC allows for a simple and straightforward production method which does not 
require special equipment, high pressures, or elevated temperatures.  
Additionally, SPAAC is a biorthogonal reaction which provides a stable, covalent linker 
between protein and PEG. Neither alkyne nor azide are reactive with common functional groups 
found in the body (Baskin & Bertozzi, 2009). This non-reactivity eliminates the possibility of 
side-reactions between residual, unreacted SPAAC groups and native proteins upon 
administration. The BSAx-R-123t-PEG8 complex will pass through a variety of environments as 
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it circulates through the body. The stable 1,2,3-triazole linker will reduce the chances of 
dissolution of the PEG complex before delivery of ligand (Massarotti et al., 2014). 
 
 
Figure 21. Conjugation of bovine serum albumin onto PEG8 via strain-promoted azide-alkyne 
cycloaddition. (a) BSA is first activated with DIBO-R-NHS at a single lysine. Activated BSA is 
attached to the PEG8 backbone via SPAAC. “R” denotes a variable spacer incorporated into the 
activating reagent. (b) DIBO-NHS and (c) DIBO-PEG4-NHS were used to activate BSA. 
 
In this study, dibenzocyclooctyl-functionalized BSA molecules (DIBO-R-BSA) will be 
conjugated onto an 8-arm PEG backbone functionalized with terminal azides (N3-PEG8) (Figure 
21). BSA will be “activated” with one of two N-hydroxysuccinimidyl ester-functionalized DIBO 
reagents (DIBO-R-NHS) via one of BSA’s 59 native lysine residues (Cline & Hanna, 1988). 
A short activator, Dibenzocyclooctyne-N-hydroxysuccinimidyl ester (DIBO-NHS), was 
used from the outset of this study. In an attempt to increase yields, the longer 
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Dibenzocyclooctyne-PEG4-N-hydroxysuccinimidyl ester (DIBO-PEG4-NHS) was added. It was 
hypothesized that once a few BSA molecules attached to the backbone, additional proteins would 
be unable to access the remaining PEG arms due to steric hindrance. The PEG4 spacer provided 
an additional 14 Å between protein and alkyne. The reduced congestion at the attachment sites 
between DIBO and N3 was expected to increase yields. Also, with easier access to the PEG 
backbone, heterogeneity of the product was expected to decrease, resulting in fewer species of 
BSAx-R-123t-PEG8. 
A 1:1 activation ratio of DIBO:BSA will be used and the PEGylation methodology will 
be optimized to give the highest yield of PEGylated protein. The degree of activation will also be 
determined using Fluorescein-NHS (Fluor-NHS) to mimic the interaction of BSA and the 
activating agents. The PEGylated complexes will then be characterized in terms of secondary 
structure, speciation, and ligand-binding capabilities. 
Materials and Methods 
Materials 
 Lyophilized BSA (Product Number A7906), DIBO-NHS (761524), DIBO-PEG4-NHS 
(764019), Fluorescein-5-EX N-hydroxysuccinimide ester (Fluor-NHS; F9551), sulfamethoxazole 
(SMZ; S7507), naproxen (NPX; N8280), and all reagents not detailed were purchased from 
Sigma-Aldrich. 
Methods 
 All experiments were carried out in 50 mM 4-Morpholinepropanesulfonic acid/0.15 M 
NaCl pH 7.2 (MOPS/NaCl) buffer unless otherwise noted. Fast protein liquid chromatography 
(FPLC) separations were performed on an ÄKTAprime plus chromatography system (Amersham 
Biosciences; 11001313) with MOPS/NaCl mobile phase. Resulting fractions were concentrated 
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with 30 kDa MW cut-off centrifuge filters (Sartorius; VS2022). Absorbance values were 
obtained on an Agilent 8453 UV-visible Spectroscopy System. BSA concentrations were 
calculated at 280 nm with an extinction coefficient of 43.824 mM-1 cm-1 and a MW of 66,430 Da 
(Hirayama, Akashi, Furuya & Fukuhara, 1990; "Thermo Scientific: Extinction Coefficients," 
2013). 
 Fatty acid removal. Fatty acid-free BSA (FAF-BSA) was prepared via an activated 
charcoal method (Chen, 1967). In short, BSA was dissolved in MOPS/NaCl. The solution was 
acidified to pH 3 and stirred on ice with 20-40 mesh particle size activated charcoal in order to 
remove any bound fatty acids. Charcoal was pelleted at 10,000 rpm and the supernatant was 
filtered through 0.2 µm cellulose filters to remove any remaining carbon. The de-fatted albumin 
solution was returned to pH 7.2 before further purification. Dimers were removed by size 
exclusion chromatography (SEC) on a pre-packed 120 mL 60 cm x 16 mm S300 FPLC column 
(GE Healthcare; 17-1167-01). 
 Activation of FAF-BSA with DIBO. Conjugation of BSA molecules onto a 40 kDa N3-
PEG8 backbone required two steps, activation and PEGylation (Figure 21). Table 5 details the 
nomenclature used to discuss these reactions. 
Table 5. Nomenclature for the Conjugation of BSA onto PEG8 via Strain-Promoted Azide-
Alkyne Cycloaddition. Reaction with complimentary azide for all DIBO-functionalized BSA 
reactions results in a 1,2,3-triazole (123t). 
	
Activator Activated BSA PEG Product 
DIBO-R-NHS 
(generic) DIBO-R-BSA BSAx-R-123t-PEG8 
DIBO-NHS 
(short) DIBO-BSA BSAx-123t-PEG8 
DIBO-PEG4-NHS 
(long) DIBO-PEG4-BSA BSAx-PEG4-123t-PEG8 
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Activation involves the attachment of a DIBO functional group onto BSA via reaction 
between an NHS-ester and the amino side-chain of lysine. DIBO-NHS and DIBO-PEG4-NHS 
stocks were prepared in dry dimethyl sulfoxide and added to 1 mM FAF-BSA to give a final 
ratio of 1:1 DIBO-R-NHS:FAF-BSA. Introduction of DIBO-R-NHS was made in small aliquots 
with mixing between additions to avoid BSA denaturation due to the organic solvent. After two 
hours at room temperature, excess activator was removed by triple-rinsing the sample through 30 
kDa centrifuge filters ("Thermo Scientific: NHS-Azide and NHS-Phosphine Reagents," 2014). 
 PEGylation of DIBO-activated FAF-BSA. N3-PEG8 (Creative PEGworks; PSB-884) 
was dissolved in MOPS/NaCl and added to 1 mM DIBO-activated FAF-BSA at 16:1 DIBO-R-
BSA:N3-PEG8. The solution was allowed to incubate at room temperature for one week with 
constant stirring. PEGylated FAF-BSA was purified via a two-phase SEC separation. The bulk 
of unreacted FAF-BSA was removed by way of an S300 FPLC column, the remainder via a 320 
mL 60 cm x 26 mm S500 column (GE Healthcare; 28-9356-07). Chromatograms from the S300 
separation were processed in PrimeView 5.0 software to determine yields as the percentage of 
total area count. 
 PEGylation optimization. Optimization of the PEGylation methodology was determined 
by monitoring the amount of BSAx-123t-PEG8 produced with varying PEGylation ratios, 
temperatures, and incubation times. PEGylation ratios were monitored at 4, 8, 16, 32, and 128:1 
DIBO-BSA:N3-PEG8. Reactions were carried out at 4oC, room temperature, and 32oC for one 
week. The time trial was performed by determing the amount of product formed after two, five, 
and seven days of incubation. Weekly assays were performed over the course of an additional 
four weeks. The baseline conditions for all PEGylation reactions were 16:1 DIBO-BSA:N3-PEG8 
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at room temperature for one week with constant stirring. Samples were passed through an S500 
column and the amount of product was determined as the percentage of total area count. 
Fluorescent labeling. The degree of activation was determined using Fluor-NHS to 
mimic the DIBO activators. Fluor-NHS has a MW of 590.56 g/mol which is similar to both DIBO-
NHS (MW 402.4) and DIBO-PEG4-NHS (MW 649.69). The activation procedure was followed, 
substituting Fluor-NHS. Unreacted fluorophore was removed via triple rinse with 50 mM 
Tricine/0.15 M NaCl pH 8.5 through 30 kDa centrifugation filters. The following calculations 
used absorbance at 280 nm (λmax for BSA) and 495 nm (λmax for Flour) to determine 
Fluorbound:FAF-BSA ("Thermo Scientific: NHS-Fluorescein," 2016). 
Molar	 FluorBSA = Abs/01 	∗ 	CAbs456 	−	 CF	 ∗ 	Abs/01  
 CF = 	Abs456	of	unreacted	FluorAbs/01	of	unreacted	Fluor 
 C	 = MW?@A	 Da ∗ 	E4566.E%MWGHIJK 	∗ 	195  
 
195 = E/016.E% of bound Fluor 
 
MWFluor = 475.47 Da (MWFluor-NHS minus MWNHS which is lost upon 
reaction with lysine) 
 
 Circular dichroism (CD). The effects on secondary structure of the PEGylation 
procedure were determined by CD. BSAx-123t-PEG8 and BSAx-PEG4-123t-PEG8 were assayed 
in 50 mM MOPS pH 7.2 at 30oC on an Olis DSM 20 CD Spectrophotometer. Ellipticity was 
monitored between 190 nm and 260 nm. Helicity was calculated with DichroWeb (Whitmore & 
Wallace, 2008) and the analysis program CDSSTR (Sreerama & Woody, 2000). Inclusion of a 
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crystal structure for HSA (Wardell et al., 2002) allowed for use of reference set SP175 (Janes, 
2009; Lees, Miles, Wien & Wallace, 2006). 
SDS-PAGE. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
was performed as an initial characterization of BSAx-R-123t-PEG8 species. The assay was 
performed on a PhastSystem (Amersham Biosciences; 18-1018-23) with a 4-15% gradient 
PhastGel (GE Healthcare; 17-0678-01), Coomassie R 350 stain (GE Healthcare; 17-0518-01), 
and high molecular weight markers (GE Healthcare; 17-0615-01).  
 Analytical ultracentrifugation (AUC). AUC was carried out in a Beckman Coulter 
ProteomeLab XL-A analytical ultracentrifuge using standard two sector cells with quartz 
windows in four- or eight-hole rotors. All sedimentation velocity experiments were performed at 
50,000 rpm with a preset scan number of 100 per cell. The reference sector was filled with 450 
µL of MOPS/NaCl and the sample sector was filled with 430 µL of sample with an absorbance at 
280 nm between 0.75 and 1.1. Path length was 1 cm. Buffer density was measured at 20.0oC in a 
Mettler/Paar Calculating Density Meter DMA 55A and the buffer viscosity was measured in an 
Anton Parr AMVn Automated Microviscometer. Data were analyzed using the program Sedfit 
(Schuck, 2000; "Sedfit," 2017). Molecular weights and sedimentation coefficients (S20,w) were 
determined using the continuous c(s) mode in the Sedfit program. Native monomeric BSA 
yielded an S20,w value of 4.04 S which agreed with published values (Shulman, 1953; Taylor, 
1952; Zhao et al., 2015). The c(s) plots were deconvoluted using non-linear least-squares fitting 
algorithms available in the Origin (v. 9.0) software package (OriginLab Corporation, 
Northampton, MA). Data were fit to multiple Gaussian components, increasing the number of 
components until residual plots (data-fit) were random and the chi square value for the fit was 
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minimal. Values reported are percentages of the total area count of peaks corresponding to 
PEGylated species. These area counts were calculated via the trapezoidal formula. 
 Fluorimetric analyses. Binding studies were performed on a Photon Technology 
International fluorimeter using Felix software (version 1.1). SMZ, a DS1 ligand, and NPX, a 
DS2 ligand, were studied to determine if PEGylation affected ligand binding capabilities. The 
number of binding sites (n) and the association constant (Ka) were calculated for BSAx-123t-
PEG8 and BSAx-PEG4-123t-PEG8. In each case, the fluorophore monitored was Trp213, found at 
the entrance to DS1 in Domain IIA. 
For SMZ, 30 µM stock solutions of FAF-BSA, BSAx-123t-PEG8, and BSAx-PEG4-123t-
PEG8 were prepared in 0.2 M Tris-HCl/0.1 M NaCl pH 7.4. SMZ was dissolved in methanol to a 
final stock concentration of 30 mM. Working SMZ stocks were prepared at 3 mM and 1 mM by 
dilution with Tris buffer. Monitoring emission between 300-380 nm upon excitation at 283 nm at 
25oC, aliquots of working SMZ stocks were titrated into a 3 µM BSA solution. 1 mM working 
stock was used up to 20 µM SMZ. 3 mM working stock was used to raise the final concentration 
to 80 µM SMZ. 
To determine n and Ka for NPX, 30 µM stock solutions of FAF-BSA, BSAx-123t-PEG8, 
and BSAx-PEG4-123t-PEG8 were prepared in 10 mM phosphate buffer pH 7.0. NPX was 
dissolved in methanol to a final stock concentration of 45 mM. A working NPX stock was 
prepared at 0.15 mM by dilution with phosphate buffer. Monitoring emission between 300-380 
nm upon excitation at 295 nm at 25oC, aliquots of working NPX stocks were titrated into a 0.725 
µM BSA solution to a final concentration of 3 µM NPX. 
Blanks for each ligand at each concentration were necessary to account for any 
fluorescence due to the ligand itself. SMZ had almost no signal under experimental conditions. 
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NPX, however, showed strong emission with maxima at approximately 350 nm. Particularly at 
high concentrations, NPX signal obscured the BSA maxima which ranges from 344 to 350 nm. 
Non-linear regression analyses were carried out using The Gnumeric Spreadsheet 
(version 1.10.16) ("The Gnome Project: The Gnumeric Spreadsheet: Free, Fast, Accurate - pick 
any three," 2011) and a modified Hill equation. In order to normalize samples, fractional 
intensities (FrInt) were used in place of raw intensities. 
FrInt	 = 	 FrIntPQR	–	FrIntPTU ∗ 	 Ligand UKZU 	+	 Ligand U +	FrIntPTU 
 FrInt	 = 	 (IntT	]^	_T`QUZ − Int6	]^	_T`QUZ)(IntPQR	]^	_T`QUZ −	 Int6	]^	_T`QUZ) 
 KQ = 1KZ 
 
Results and Discussion 
Methodology Optimization 
The PEGylation portion of the polymerization procedure was optimized by varying the 
PEGylation ratios, temperature, and reaction time. FAF-BSA was activated at a 1:1 mole ratio 
with DIBO-NHS, triple-rinsed with MOPS/NaCl, and concentrated to 1 mM with 30 kDa 
centrifuge filters before PEGylation. Samples were evaluated for BSAx-123t-PEG8 content as the 
percent of the total area count after separation on an S500 column. 
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(a) 
 
  PEGylation ratio (DIBO-BSA:N3-PEG8) 
Temperature  
(b) 
 
 
Figure 22. Optimization of the PEGylation procedure for DIBO-activated FAF-BSA. 
(a) PEGylation ratio and temperature were varied to produce the highest yields. (b) A time trial 
of PEGylation at 1:1 activation with DIBO-NHS, 16:1 DIBO-BSA:N3-PEG8 at room 
temperature. 
 
 PEGylation ratio proved to be the most effective control over product formation (Figure 
22). Varying PEGylation ratios from 4:1 DIBO-BSA:N3-PEG8 to 128:1 showed a maximum of 
31% BSAx-123t-PEG8 product formed at 16:1. When this ratio was pushed to a higher excess of 
DIBO, the lowest yield of 4% was obtained at 128:1. This could be due to dilution of the N3-
PEG8, resulting in less interaction between azide and alkyne. When in excess of N3-PEG8, a 
similarly low 9% is obtained. At 16:1, the optimal balance between DIBO-BSA:N3-PEG8 ratio 
and individual reactant concentrations was found. 
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 Temperature proved to be the least effective control. Assays performed at room 
temperature generated the highest yields. Slightly less product was formed at a lower 
temperature (4oC) with similar results at an elevated temperature (37oC). The negligible 
difference in yields suggests an indifference to temperature. 
 One week of reaction time was sufficient to generate a considerable amount of product. 
Yields trended upwards over five weeks. While reacting for longer periods generated more 
product, majority of the BSAx-123t-PEG8 was formed within the first seven days. Given an 
already extensive reaction time, additional weeks of incubation were deemed unnecessary for 
only slightly more product. 
Effects on Secondary Structure 
Helicity content for BSA has been reported between 56-66% (Das et al., 2017; Moriyama 
et al., 2008). Characteristic minima at 210 nm and 220 nm were seen in all spectra of PEGylated 
BSA (Figure 23). Unmodified FAF-BSA contained 59.2 ± 2.2% α-helix. Neither BSAx-123t-
PEG8 (63.4 ± 2.1%) nor BSAx-PEG4-123t-PEG8 (59.3 ± 3.5%) showed any loss in secondary 
structure.  
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Figure 23. Circular dichroic spectra of FAF-BSA and strain-promoted azide-alkyne 
cycloaddition PEGylated products. FAF-BSA (---); BSAx-123t-PEG8 (blue); 
BSAx-PEG4-123t-PEG8 (orange). 
 
Degree of Activation 
A 1:1 activator:FAF-BSA mole ratio was necessary to reduce the risk of over-activation 
resulting in a single BSA making multiple connections to a single or multiple N3-PEG8 
backbones. The degree of activation was quantified using Fluor-NHS that would mimic the 
interactions between FAF-BSA and either activating agent. By monitoring the absorbance 
maxima at 280 nm and 495 nm, an average of 0.75 ± 0.04 Fluor per BSA was calculated. By 
controlling the mole ratio of activator:FAF-BSA, the odds of multiple attachments was greatly 
decreased. 
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BSAx-R-123t-PEG8 Yields 
While the risk of over-PEGylation was limited, so too was the yield of PEGylated 
protein. By integrating chromatograms from the S300 separation (Figure 24a), yields were 
calculated for both DIBO reagents. The hypothesis that an additional 14 Å would be sufficient to 
greatly increase yields was proven incorrect. The shorter DIBO-NHS produced an average of 
23.6% BSAx-123t-PEG8 (range: 19.5-31.0%). The longer DIBO-PEG4-NHS generated only 
slightly more product (average: 25.3%, range: 19.1-36.5%). The additional length of the 
extended alkyne activating agent did not result in substantially higher yields but does suggest 
that further separation of the bulky BSA from the bulky backbone of PEG8 may enhance yields.  
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BSAx-R-123t-PEG8 Speciation 
 Purified BSAx-123t-PEG8 and BSAx-PEG4-123t-PEG8 were run through an SDS-PAGE 
4-15% gradient gel. A band at approximately 116 kDa corresponds to a combination of dimeric 
BSA and BSA1-R-123t-PEG8 conjugates (Figure 25). High molecular weight bands in the 
separation zone and a heavy band retained in the stacking zone were seen for both BSAx-123t-
PEG8 and BSAx-PEG4-123t-PEG8. This suggests a minimum of three to four species of 
PEGylated FAF-BSA were formed with either activating agent. The bands likely correspond to 
PEG8 +2 FAF-BSA (172 kDa), +3 FAF-BSA (238 kDa), and +4 FAF-BSA (304 kDa). Smearing 
in the separating zone was due to the interaction of the PEG backbone with the polyacrylamide 
gel as well as variability of the specific lysine residue activated by the DIBO reagents. 
Manufacturer specifications quote the upper limit of separation for these gels at 300 kDa for non-
PEGylated proteins. It is inferred that material retained in the stacking zone consists of a 
minimum of five FAF-BSA molecules attached to the PEG8 backbone with a MW of 
approximately 370 kDa. 
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Figure 25. Electrophoretic separation of species of bovine serum albumin PEGylated via strain-
promoted azide-alkyne click chemistry. Lane 1: FAF-BSA; Lane 2-3: BSAx-123t-PEG8; Lane 4-
5: BSAx-PEG4-123t-PEG8; Lane 6: High molecular weight marker. 
 
The speciation of purified PEGylated BSA was examined by AUC. The majority of the 
PEGylated species generated with both activators were complexes containing BSA2-4. These 
species accounted for 55% of BSAx-123t-PEG8 (Figure 26) and 65% of BSAx-PEG4-123t-PEG8 
(Figure 27). BSA5-7-R-123t-PEG8 conjugates were present in much lower concentrations, making 
up 31% and 14% of short and long activator species, respectively. The shorter DIBO-BSA 
resulted in 8% BSA1 species while the longer DIBO-PEG4-BSA generated 19%. The peaks 
found at S20,w values greater than 15 S are thought to be a mixture of BSA8-R-123t-PEG8 species 
and complexes formed from over-activated protein.  
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Peak 1 2 3 4 5 6 7 8 9 
S20,w 3.23 4.65 6.26 7.47 9.09 10.3 12.1 14.1 16.8 
MWcalc 
(kDa) 57.5 92.2 143 196 283 nr 396 493 609 
MWtheor 
(kDa) 66 106 172 238 304 370 436 502 n/a 
# BSA 
conjugated monomer 1 2 3 4 5 6 7 n/a 
% Area 
Count n/a 8 17 18 20 11 11 9 6 
 
Figure 26. Analytical ultracentrifugation analysis of BSAx-123t-PEG8. % Area Count values are 
the percent of PEGylated species only. nr: not reported; n/a: not applicable. 
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Peak 1 2 3 4 5 6 7 8 9 
S20,w 3.03 4.65 6.06 7.27 8.89 10.5 12.1 13.9 15.8 
MWcalc 
(kDa) 71.3 135 201 279 nr 481 nr nr nr 
MWtheor 
(kDa) 66 106 172 238 304 370 436 502 n/a 
# BSA 
conjugated monomer 1 2 3 4 5 6 7 n/a 
% Area 
Count n/a 19 25 26 14 8 4 2 2 
 
Figure 27. Analytical ultracentrifugation analysis of BSAx-PEG4-123t-PEG8. % Area Count 
values are the percent of PEGylated species only. nr: not reported; n/a: not applicable. 
 
AUC results corresponded well with the SDS-PAGE analysis. Each purified sample 
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molecular weight material was present but a lower concentration. The longer DIBO-PEG4-NHS 
generated only slightly more PEGylated species than DIBO-NHS based on SEC data. However, 
the distribution of those species was smaller, generating a more homogenous final product. 
Ligand Binding Capabilities 
 To compare the effects of PEGylation on the ability of conjugated BSA to bind ligands, 
fluorescent emission intensity of Trp213 was monitored. The ability of PEGylated species to 
bind ligands in DS2 was probed with NPX. Crystal structures of de-fatted bovine, equine, and 
leporine serum albumins complexed with NPX have been reported (Bujacz et al., 2014). In each 
species of serum albumin, NPX preferentially binds to DS2. A second molecule of NPX binds to 
fatty acid binding site 6. In leporine serum albumin, a tertiary site for NPX is found in a 
superficial cleft in subdomain IIIA while in BSA, the tertiary binding site is DS1. Experimental 
values for NPX in the presence of FAF-BSA, BSAx-123t-PEG8, and BSAx-PEG4-123t-PEG8 
were consistent with published values (Table 6). NPX was tightly bound by all species of BSA. 
Table 6. Association Constants (Ka) and Number of Binding Sites (n) for BSAx-123t-PEG8 and 
BSAx-PEG4-123t-PEG8 for Sulfamethoxazole and Naproxen. 
 
 SMZ NPX 
Sample Ka (x103 M-1) n Ka (x107 M-1) n 
FAF-BSA 2.03 ± 0.18 0.9 ± 0.1 0.40 ± 0.13 0.4 ± 0.1 
BSAx-123t-PEG8 0.39 ± 0.29 0.8 ± 0.1 0.79 ± 0.61 2.4 ± 1.1 
BSAx-PEG4-123t-PEG8 0.15 ± 0.06  0.8 ± 0.05  3.55 ± 1.6 0.9 ± 0.2 
Lit. values1,2 3.55-15.6 0.9-1.0 0.12-3.70 0.6-3 
 
1SMZ values were published by Naik et al. (2009; 2015), Rajendiran & Thulasidhasan (2015), and Wang et al. 
(2014). 
 
2NPX values were reported by Banerjee et al. (2006), Bou-Abdallah et al. (2016), Fielding et al. (2005), and Honoré 
& Brodersen (1984). Bujacz et al. (2014) have reported a crystal structure (PDB ID: 4OR0) for BSA complexed 
with three NPX molecules. 
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 Binding of NPX to FAF-BSA, BSAx-123t-PEG8, and BSAx-PEG4-123t-PEG8 showed 
similar trends (Figure 28). BSA in the absence of NPX had a maximum emission wavelength at 
344 nm. With increasing amounts of NPX, a red shift resulted in a maximum at 350 nm. This is 
consistent with binding to a site adjacent to the fluorophore. In this case, the fluorophore studied 
was Trp213 found in Domain IIA at the mouth of DS1. As ligand binds to DS2, slight 
conformational changes exposed Trp213 to the solvent, causing a red shift. 
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Figure 28. Fluorimetric spectra and non-linear regression of BSAx-123t-PEG8 and BSAx-PEG4-
123t-PEG8 in the presence of naproxen. Spectra for (a) BSAx-PEG4-123t-PEG8 and 
(b) FAF-BSA in the presence of increasing concentrations of NPX. BSAx-123t-PEG8 spectra 
followed similar trends as both FAF-BSA and BSAx-PEG4-123t-PEG8. (c) Non-linear regression 
analyses for FAF-BSA (black ¯), BSAx-123t-PEG8 (blue r), and BSAx-PEG4-123t-PEG8 
(orange ). Experimental data is represented as symbols while calculated data points are lines. 
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DS1, however, appears to be greatly affected by the covalent attachment of PEG8. FAF-
BSA values were similar to published values for both Ka and n for SMZ studies (Table 6). 
However, both BSAx-123t-PEG8 and BSAx-PEG4-123t-PEG8 demonstrated a greatly reduced 
affinity for SMZ. Spectra for all forms of BSA followed similar trends (Figure 29). Intensities 
decreased as SMZ concentration increased. The signal from Trp213 was quenched in the 
presence of the ligand though it was not tightly bound in either form of PEGylated BSA. 
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Figure 29. Fluorimetric spectra and non-linear regression of BSAx-R-123t-PEG8 in the presence 
of sulfamethoxazole. Spectra for (a) BSAx-123t-PEG8 and (b) FAF-BSA in the presence of 
increasing concentrations of SMZ. BSAx-PEG4-123t-PEG8 spectra followed similar trends as 
both FAF-BSA and BSAx-123t-PEG8. (c) Non-linear regression analyses for FAF-BSA (black 
¯), BSAx-123t-PEG8 (blue r), and BSAx-PEG4-123t-PEG8 (orange ). Experimental data is 
represented as symbols while calculated data points are lines. 
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 Similar results were seen for PEGylation at Cys34 with maleimido-PEG8. Upon 
modification of this single residue in Domain IA, the affinity for SMZ was reduced to 0.19 x103 
M-1. It was hypothesized that conformational changes induced by PEGylation at Cys34 altered 
the structure of DS1 which is found in Domains IB and IIA. The conditions employed for 
SPAAC PEGylation allow for selective modification of lysines, but do not preferentially alter 
specific lysines on the surface of BSA. Given the results from the modification of Cys34, it is 
possible that lysines in Domain I are preferentially altered by DIBO-R-NHS activators. 
Conclusions 
 The conjugation of BSA onto a PEG8 backbone via SPAAC proved successful using both 
forms of DIBO activator. The PEGylation process proved to be most dependent on the ratio of 
DIBO-BSA:N3-PEG8 with an optimal reaction ratio of 16:1. 
The shorter DIBO-NHS PEGylated an average of 23% FAF-BSA. The extended DIBO-
PEG4-NHS yielded only slightly more product at 25%. The additional 14 Å was of little 
assistance in terms of yield. The longer activating agent did, however, produce a more 
homogenous final product, generating a majority of BSA2-4-R-123t-PEG8 species.  
In terms of ligand binding capabilities, neither activating agent greatly affected BSA’s 
ability to bind NPX, a model DS2 ligand. DS1 was affected by PEGylation as evidenced by 
greatly reduced association constants. 
The PEGylation procedure proved to be successful regardless of the activating agent. 
High molecular weight complexes of FAF-BSA were still capable of binding ligands to one of 
the main drug binding sites. These complexes show promise as a possible drug delivery method. 
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CHAPTER V 
STUDIES ON THERMAL STABILITY AND 
THE EFFECTS OF PASTEURIZATION ON  
PEGYLATED MULTI-ALBUMIN COMPLEXES 
Introduction 
PEGylation has become a common method of increasing circulatory lifetimes of protein-based 
therapies. Due to increased hydrodynamic volume conferred by the attachment of a polyethylene 
glycol (PEG) backbone, the PEGylated complexes appear several times larger than molecular 
weight would suggest (Plesner, Fee, Westh & Nielsen, 2011; Veronese, Mero & Pasut, 2009). 
Increased size allows the particle to escape elimination and remain in circulation for longer 
periods of time. 
 In order to increase solubility and provide protection for hydrophobic drugs, serum 
albumins have been incorporated into drug carriers (Anhorn, Wagner, Kreuter, Langer & von 
Briesen, 2008; Desai, 2008). Bovine serum albumin (BSA) contains a multitude of binding sites 
which are tailored for endogenous molecules including fatty acids and heavy metals 
(Bhattacharya, Grüne & Curry, 2000; Rózga, Sokołowska, Protas & Bal, 2007). Fatty acid 
binding pockets, have been found to bind drugs but are typically secondary or tertiary options. 
The primary hydrophobic cavities for drug binding were initially characterized by Sudlow et al. 
(1975, 1976). Deemed Drug Sites I and II (DS1 and DS2), these sites are able to house a variety 
of ligands (Ghuman et al., 2005; Yamasaki, Chuang, Maruyama & Otagiri, 2013).  
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DS1 is found at the interface of Domains IB and IIA while DS2 resides in Domain IIIA. Access 
to these sites is controlled via flexing of the local tertiary structure.  
BSA contains three highly helical domains (I, II, and III), each divided into two 
subdomains (A and B) which are connected by long loops. Conformational flexibility of each 
domain is conferred by helical bending and subdomain orientation is controlled by movement of 
the loops. These types of movements open and close the various binding sites dotted throughout 
the structure. 
While the exterior of albumin is somewhat flexible, the interior of the protein is rigidly 
maintained via 17 disulfide bridges. Subdomain A is stapled together by four of these while two 
bridges stabilize subdomain B. An exception is Subdomain IA, which contains only three bridges 
(Bujacz, 2012). A single free cysteine at position 34 is found on the surface of Domain I. This 
superficial residue allows for selective, covalent attachment of a PEG chain. 
Modifications of cysteines are often made via thiol-maleimide reactions, resulting in a 
thioether linkage (Anhorn et al., 2008; Manjula et al., 2003; K. D. Webster et al., 2017). This 
class of reaction has become attractive due to typically simple reaction conditions as it can 
readily proceed in an aqueous environment and requires neither catalyst nor high temperatures. 
In addition to this free cysteine, 59 lysines are scattered throughout BSA. Terminal amino 
groups allow for modification with a number of different functional groups. One of the more 
common reactions is via an N-hydroxysuccinimide (NHS) ester (Cline & Hanna, 1988). The 
reactivity between NHS and lysine provides a convenient way to anchor another functional 
group to the protein. 
The abundance and easy access to these lysines allows for attachment of a foreign moiety 
without the need for recombinant techniques. Strain-promoted azide-alkyne cycloaddition 
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(SPAAC), a class of “click” chemistry, results a highly stable 1,2,3-triazole linker. Additionally, 
both azide and alkyne are biorthogonal in that they are absent from nature and non-reactive with 
naturally-occurring functional groups (Agard, Prescher & Bertozzi, 2004; Baskin & Bertozzi, 
2009). By using the NHS-lysine reaction, a strained alkyne may be covalently attached to BSA. 
PEG functionalized with the complimentary azido moiety may then be reacted with the alkyne-
activated BSA to link the two molecules. 
PEGylation, while providing many benefits to the modified protein, have also been 
shown to affect thermal stability, which may be described by the temperatures of denaturation 
(Tm) and aggregation (Tagg). Tm is the temperature at which a protein is 50% unfolded (K. W. 
Olsen, 1994). Tagg describes the ability of both native and non-native forms of a protein to form 
oligomerize (Plesner et al., 2011; Wetzel et al., 1980). Both are important parameters to consider 
during the development of protein-based drug delivery systems as they factor into shelf-life and 
terminal sterilization. 
In the case of BSA, typical Tm is approximately 82oC as determined by differential 
scanning calorimetry (Plesner et al., 2011). Attachment of a single linear 40 kDa PEG chain at 
Cys34, lowered Tm to 80oC. Tagg, on the other hand, increased upon PEGylation. Unmodified 
BSA aggregated at 71oC while the 40 kDa PEG-BSA species had a Tagg of 82oC. 
Steam sterilization, or autoclaving, is the most common approach used in pharmaceutical 
production. Materials are heated to 121oC at 1.5 bar for a minimum of 15 minutes. These 
conditions are likely to denature protein components. For this reason, protein-based formulations 
are sterilized aseptically, an approach where each component is sterilized individually before 
preparation of the final product (Baez & Assaf-Anid, 2008; Yaman, 2001). 
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Albumin-based components are pasteurized at 60oC for ten hours. In order to maintain 
helicity, the stabilizing reagents N-acetyl-L-tryptophan (NAT) and sodium caprylate are included 
at mole ratios of 5.5:1 stabilizer:albumin (Anraku et al., 2004; Christiansen & Skotland, 2010; 
Farcet, Kindermann, Modrof & Kreil, 2012; Gellis et al., 1948). 
High concentrations of these stabilizers have been implicated in the reduced efficacy of 
albumin solutions administered to patients with impaired liver function. For these patients, 
albumin, which is produced in the liver, is typically found at extremely low concentrations. 
Exogenous albumin, which has been pasteurized with NAT and caprylate, is often administered 
intravenously to compensate. Both reagents have been shown to have an affinity for DS2, a site 
also shared by metabolites commonly formed at high levels in patients with liver disease (Kawai 
et al., 2017). 
In healthy individuals, NAT and caprylate bind to albumin. Albumin production is 
unimpaired and routine transport of NAT, caprylate, and other metabolites is unaffected. In 
impaired individuals, elevated levels of these toxins are often found due to direct competition 
with stabilizers for a single high affinity binding site (Stange et al., 2011).  
These additives also pose a potential problem for production of albumin-based drug 
delivery systems. Their preference for DS2 results in competition between NAT, caprylate, and 
the drug molecule being administered. For naproxen (NPX), a known DS2 ligand, affinity was 
40 times lower in pharmaceutical-grade albumin solutions (i.e. pasteurized with NAT and 
caprylate) than in research-grade albumin (i.e. un-pasteurized) (H. Olsen, Andersen, Nordbo, 
Kongsgaard & Bormer, 2004). 
In this study, the effects of PEGylation on the thermal stability of BSA were examined. 
Three PEGylated BSA complexes were prepared. In the first case, native Cys34 of BSA was 
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used as a site of direct attachment of an eight-armed PEG backbone with terminal maleimides 
(Mal-PEG8) resulting in a thioether linker. For the two others, BSA were attached to PEG8 via 
SPAAC click chemistry. BSA was “activated” with either a short- or long-chain 
dibenzocyclooctyne-functionalized N-hydroxysuccinimidyl ester (DIBO-NHS; DIBO-PEG4-
NHS). Activated BSA were attached to an azido-functionalized PEG8 backbone (N3-PEG8) 
resulting in a 1,4-disubstituted, 1,2,3-triazole. Changes in the absorbance at 300 nm as a function 
of temperature were used to calculate Tagg while Tm was determined for each PEG species by 
circular dichroism (CD). PEGylated BSA, pre-loaded with NPX, were pasteurized in the absence 
of NAT and caprylate to determine if a combination of PEGylation and bound ligand would 
allow for omission of these stabilizing compounds. 
Materials and Methods 
Materials 
 Lyophilized BSA (Product Number A7906), DIBO-NHS (761524), DIBO-PEG4-NHS 
(764019), NPX (N8280), and all reagents not detailed were purchased from Sigma-Aldrich. 
Methods 
 All experiments were carried out in 50 mM 4-Morpholinepropanesulfonic acid/0.15 M 
NaCl pH 7.2 (MOPS/NaCl) buffer unless otherwise noted. Fast protein liquid chromatography 
(FPLC) separations were performed on an ÄKTAprime plus chromatography system (Amersham 
Biosciences; 11001313) with MOPS/NaCl mobile phase. Resulting fractions were concentrated 
with 30 kDa molecular weight cut-off centrifuge filters (Sartorius; VS2022). Absorbance values 
were obtained on an Agilent 8453 UV-visible Spectroscopy System at 280 nm. Concentrations of 
BSA were calculated with an extinction coefficient of 43.824 mM-1 cm-1 and a molecular weight 
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of 66,430 Da (Hirayama, Akashi, Furuya & Fukuhara, 1990; "Thermo Scientific: Extinction 
Coefficients," 2013). 
 Fatty acid removal. Fatty acid-free BSA (FAF-BSA) was prepared via an activated 
charcoal method (Chen, 1967). In short, BSA was dissolved in MOPS/NaCl. The solution was 
acidified to pH 3 and stirred on ice with 20-40 mesh particle size activated charcoal in order to 
remove any bound fatty acids. Charcoal was pelleted at 10,000 rpm and the supernatant was 
filtered through 0.2 µm cellulose filters to remove any remaining carbon. The de-fatted albumin 
solution was returned to pH 7.2 before further purification. Dimers were removed by size 
exclusion chromatography (SEC) on a pre-packed 120 mL 60 cm x 16 mm S300 FPLC column 
(GE Healthcare; 17-1167-01). 
 PEGylation of FAF-BSA. Table 7 details the nomenclature used to discuss these 
reactions. Cys34, requiring no further activation, was attached to PEG8 with a thioether (te) 
linkage formed by reaction with Mal-PEG8. For SPAAC reactions, the complimentary azide for 
all DIBO-functionalized BSA reactions was N3-PEG8, resulting in a 1,2,3-triazole (123t). 
Table 7. Nomenclature for PEGylation of Bovine Serum Albumin via Thiol-Maleimide and 
Strain-Promoted Azide-Alkyne Cycloaddition Reactions. 
	
Activator Activated BSA PEG8 PEG Product 
Thiol-Maleimide 
n/a n/a Mal-PEG8 BSAx-te-PEG8 
 Strain-Promoted Azide-Alkyne Cycloaddition  
DIBO-R-NHS 
(generic) DIBO-R-BSA 
N3-PEG8 
BSAx-R-123t-PEG8 
DIBO-NHS 
(short) DIBO-BSA BSAx-123t-PEG8 
DIBO-PEG4-NHS 
(long) DIBO-PEG4-BSA BSAx-PEG4-123t-PEG8 
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 PEGylation of Cys34. 40 kDa Mal-PEG8 (Creative PEGworks; PSB-864) was dissolved 
in MOPS/NaCl and added to 1 mM FAF-BSA at 8:1 FAF-BSA:Mal-PEG8. The solution was 
allowed to incubate at room temperature for one week with constant stirring.  
PEGylation with SPAAC. Conjugation of BSA molecules onto a 40 kDa N3-PEG8 
backbone required two steps, activation and PEGylation. Activation involves the attachment of a 
DIBO functional group onto BSA via reaction between an NHS-ester and the amino side-chain 
of lysine. DIBO-NHS and DIBO-PEG4-NHS stocks were prepared in dry dimethyl sulfoxide and 
added to 1 mM FAF-BSA to give a final ratio of 1:1 DIBO-R-NHS:FAF-BSA. Introduction of 
DIBO-R-NHS was made in small aliquots with mixing between additions to avoid BSA 
denaturation due to the organic solvent. After two hours at room temperature, excess activator 
was removed by triple-rinsing the sample through 30 kDa centrifuge filters ("Thermo Scientific: 
NHS-Azide and NHS-Phosphine Reagents," 2014). 
N3-PEG8 (Creative PEGworks; PSB-884) dissolved in MOPS/NaCl was added to 1 mM 
DIBO-activated FAF-BSA at 16:1 DIBO-R-BSA:N3-PEG8. The solution was allowed to 
incubate at room temperature for one week with constant stirring. 
Purification of PEGylated BSA. PEGylated FAF-BSA was purified via a two-phase SEC 
separation. The bulk of unreacted FAF-BSA was removed by way of an S300 FPLC column, the 
remainder via a 320 mL 60 cm x 26 mm S500 column (GE Healthcare; 28-9356-07). 
 Spectroscopic evaluation of aggregation. Tagg was determined by monitoring 
absorbance at 300 nm as samples were heated from 30 oC to 100oC over two hours. Samples 
were initially assayed in MOPS/NaCl. Due to a lack of aggregation of the PEGylated samples, 
the buffer was further modified with 1.5 M Guanidinium chloride (GdmCl) and 0.4% (v/v) 2-
Mercaptoethanol (βME). The maximum temperature was held for an additional 20 minutes to 
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ensure the maximum absorbance had been reached. Tagg was calculated following the two-state 
method detailed by Olsen (1994). 
Additionally, the absorbance at 300 nm was monitored for samples prepared in 
MOPS/NaCl/0.4% βME/1.5 M GdmCl at 30oC for 2 hours 20 minutes. This ensured that 
unfolding was not due solely to the high concentrations of denaturing reagents.  
 Circular dichroic evaluation of denaturation. The effect of PEGylation on the thermal 
stability of each of these complexes was determined by CD. Samples were diluted to 0.15 mg/mL 
in 50 mM MOPS pH 7.2 and heated from 30oC to 90oC in an Olis DSM 20 CD 
Spectrophotometer. Spectra were collected at 30, 40, 50, 60, 63, 66, 70, 80, and 90oC over the 
range of 190-260 nm with a 1 nm step-size. Helicity was calculated with DichroWeb (Whitmore 
& Wallace, 2008) and the analysis program CDSSTR (Sreerama & Woody, 2000). Inclusion of a 
crystal structure for human serum albumin (Wardell et al., 2002) allowed for use of reference set 
SP175 (Janes, 2009; Lees, Miles, Wien & Wallace, 2006). Helicity at each temperature was 
compared to that of 30oC to calculate the % Remaining Helicity. A plot of % Remaining Helicity 
as a function of temperature was used to calculate Tm. 
 Pasteurization studies. To determine the necessity for the stabilizing agents NAT and 
caprylate in pasteurization, PEGylated BSA samples were diluted to 0.15 mg/mL in 50 mM MOPS 
pH 7.2 and incubated at 60oC for ten hours in the presence and absence of NPX. A 150 mM NPX 
stock prepared in methanol was further diluted to a working stock concentration of 0.5 mM with 
MOPS buffer. Samples were loaded at a mole ratio of 3:1 BSA:NPX prior to incubation. Control 
samples were held at 4oC for the duration of all experiments. All samples were brought to room 
temperature before further analysis. 
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 Circular dichroic evaluation of secondary structure. CD spectra of pasteurized samples 
were collected at 30oC under the conditions described above. For neat solutions of NPX, no 
signal was observed for NPX under these conditions. 
 Fluorimetric evaluation of naproxen binding. Binding studies were performed on a 
Photon Technology International fluorimeter using Felix software (version 1.1). NPX was 
studied to determine if pasteurization in the absence of stabilizing agents affected ligand binding 
in DS2. The number of binding sites (n) and the association constant (Ka) were calculated. 
30 kDa centrifuge filters were used to concentrate pasteurized BSA and exchange MOPS 
buffer for 10 mM phosphate buffer pH 7.0. 30 µM BSA stock solutions were prepared in 
phosphate buffer. NPX was dissolved in methanol to a final stock concentration of 45 mM. A 
working NPX stock was prepared at 0.15 mM by dilution with phosphate buffer. Monitoring 
emission between 300-380 nm upon excitation at 295 nm at 25oC, aliquots of working NPX 
stocks were titrated into a 0.725 µM BSA solution to a final concentration of 3 µM NPX. 
NPX blanks at each concentration were necessary to account for any fluorescence due to 
the ligand itself. NPX showed strong emission with maxima at approximately 350 nm. 
Particularly at high concentrations, NPX signal obscured the BSA maxima which ranges from 
344 to 350 nm. 
Non-linear regression analyses were carried out using The Gnumeric Spreadsheet (version 
1.10.16) ("The Gnome Project: The Gnumeric Spreadsheet: Free, Fast, Accurate - pick any 
three," 2011) and a modified Hill equation. In order to normalize samples, fractional intensities 
(FrInt) were used in place of raw intensities.  
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Results and Discussion 
Temperature of Aggregation (Tagg) 
Initial experiments were performed in MOPS/NaCl (Figure 30a). However, neither FAF-
BSA nor any of the PEGylated species peaked under these conditions. In order to further weaken 
the secondary structure of BSA, 0.4% (v/v) βME was added to MOPS/NaCl to reduce the 17 
disulfide bridges of BSA. FAF-BSA and BSAx-123t-PEG8 denatured and aggregated under these 
conditions but BSAx-te-PEG8 and BSAx-PEG4-123t-PEG8 still did not peak (Figure 30b). 
MOPS/NaCl/0.4% (v/v) βME was further modified with 1.5 M GdmCl. With a high 
concentration of a strong chaotrope and reducing agent, all species of BSA peaked (Figure 30c). 
The decrease in signal after maximum absorbance was due to aggregates precipitating and 
settling. Samples incubated at 30oC for the full run-time showed no change in absorbance at 300 
nm, indicating that denaturation was not due solely to the presence of high concentrations of 
GdmCl and βME. 
FAF-BSA had the lowest Tagg of 72.5oC (Table 8). BSAx-123t-PEG8 (91.8oC) and BSAx-
PEG4-123t-PEG8 (92.9oC) had significantly higher Tagg values with similar peak shapes. BSAx-
te-PEG8 reached the 50% mark at a higher temperature (77.5oC) than FAF-BSA but the signal 
began increasing at a lower temperature.  
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Table 8. Temperatures of Denaturation and Aggregation for PEGylated BSA Species. 
Sample Tagg (oC) Tm (oC) ΔTm (oC) 
FAF-BSA 72.5 ± 5.3 81.2 ± 4.1 0 
BSAx-te-PEG8  77.5 ± 5.3 77.7 ± 0.9 -3.5 
BSAx-123t-PEG8 91.8 ± 2.0 69.4 ± 3.6 -11.8 
BSAx-PEG4-123t-PEG8 92.9 ± 2.6 76.0 ± 3.2 -5.2 
 
The broadening of the BSAx-te-PEG8 peak was attributed to the dissolution of the 
thioether linker in the presence of high concentrations of excess thiol in the form of βME. 
Studies have explored the dissociation of antibody-drug conjugates due to this phenomenon 
(Alley et al., 2008; Shen et al., 2012). Following intravenous administration to mice, the 
thioether linkage reverted back to thiol-containing antibody and maleimido-functionalized drug, 
which covalently bound to Cys34 of native serum albumin. To stabilize the thioether, 
bromination of the maleimide moiety and hydrolysis of the succinimide to succinic acid have 
been explored and provide intriguing options (Fontaine, Reid, Robinson, Ashley & Santi, 2015; 
Smith et al., 2015). 
The shape of BSAx-te-PEG8 in Figure 30c is due to the gradual dissolution of the 
thioether and subsequent denaturation and aggregation of the released BSA. The triazole of 
BSAx-R-123t-PEG8 species provides a thermally stable linker and results in a sharper peak. 
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(a) (b) 
  
(c)  
 
 
Figure 30. Change in absorbance as a function of temperature for the determination of Tagg. (a) 
Aggregation was minimal in MOPS/NaCl. (b) Addition of βME to the buffer resulted in 
aggregation of some species. (c) All samples aggregated at measurable temperatures in 50 mM 
MOPS/0.15 M NaCl/0.4% βME/1.5 M GdmCl pH 7.2. FAF-BSA (black); BSAx-te-PEG8 (red); 
BSAx-123t-PEG8 (blue); BSAx-PEG4-123t-PEG8 (orange). Dashed lines correspond to 50% 
aggregation.  
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Temperature of Denaturation (Tm) 
CD spectra for all species of BSA showed characteristic minima at 210 nm and 220 nm at 
30oC, indicating highly α-helical protein (Figure 31). The helicity for each species ranged 
between 59-63% which is in agreement with published values of 56-66% (Das et al., 2017; 
Moriyama et al., 2008). As temperature increased, these valleys became less defined and helicity 
decreased. 
 
 
Figure 31. Temperature-induced changes in circular dichroic spectra. Definition of valleys at 210 
and 220 nm of FAF-BSA was lost as temperature increased. BSAx-te-PEG8, BSAx-123t-PEG8, 
and BSAx-PEG4-123t-PEG8 followed this same trend. 
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 Tm was calculated as the temperature at which 50% of the original helical content was 
lost. For FAF-BSA and all three types of PEGylated complexes, helicity slowly decreased up to 
60oC where the values dropped rapidly to minima at 90oC (Figure 32).  
(a) (b) 
  
(c) (d) 
  
 
Figure 32. Change in helicity as a function of temperature for the determination of Tm. (a) FAF-
BSA; (b) BSAx-te-PEG8; (c) BSAx-123t-PEG8; (d) BSAx-PEG4-123t-PEG8. n/a: not applicable. 
 
Unmodified FAF-BSA had the highest Tm at 81.2oC (Table 8). This is in agreement with 
the published value of 82.5oC (Plesner et al., 2011). 
The effect seen with PEGylated species on Tm is not due to the type or size of PEG 
backbone used as evidenced by BSAx-te-PEG8. For modifications at Cys34, neither a straight-
chain nor branched PEG caused a significant change in denaturation temperature. Attachment of 
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a branched 40 kDa PEG8 backbone resulted in a decrease in Tm by 3.5oC, which is similar to the 
published 2oC decrease with a straight chain 40 kDa Mal-PEG. As reported by Plesner et al. 
(2011), the decrease in Tm of PEGylated BSA was approximately 2oC for all species of linear 5-
60 kDa PEG, regardless of the molecular weight of the PEG chain. 
The drastic change in lysine-modified PEGylated BSA may be related to the proximity of 
DIBO to the surface of the protein. Modification of a lysine with the extended DIBO-PEG4-NHS 
activator resulted in a decrease in Tm by 5.2oC while the largest difference of 11.8oC was seen 
with the shorter DIBO-NHS activator. DIBO, being a bulky, hydrophobic group, is capable of 
altering the surface chemistry of BSA. This is likely the case for BSAx-123t-PEG8, where the 
activating agent lacks a spacer. In BSAx-PEG4-123t-PEG8, the added space between DIBO and 
the surface of BSA lessened the effect of hydrophobic interactions. Addition of a nonpolar patch 
onto the exterior of BSA greatly affected solvent interaction and may have promoted 
denaturation. 
Effects of Pasteurization on Secondary Structure and Ligand Binding 
The effects of pasteurization without stabilizing reagents was monitored by CD and NPX 
binding studies. In the absence of NPX, up to 18% of total helicity was lost (Figure 33). BSAx-
PEG4-123t-PEG8 lost only 7%, further strengthening the argument that increasing the distance 
between protein and PEG8 may further stabilize the complex. 
Helicity was maintained after addition of NPX at 4oC. Upon pasteurization, all samples 
consistently lost 7-10% of the original helicity. NPX has been found to bind with an association 
constant (Ka) on the order of 107 M-1. Addition of a tightly bound ligand proved to stabilize all of 
these species of BSA. This is most significant for BSAx-te-PEG8 as helicity was restored to 
levels comparable to BSAx-R-123t-PEG8 species.  
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 60oC 4oC 60oC  
 w/o NPX w/ NPX w/ NPX  
 
% Helicity 
(% Remaining) 
FAF-BSA 
(black) 
BSAx-te-PEG8 
(red) 
BSAx-123t-PEG8 
(blue) 
BSAx-PEG4-123t-PEG8 
(orange) 
 4oC w/o NPX  
57.1 +/- 4.0 56.3 ± 2.5 55.5 ± 2.1 56.5 ± 1.7 
 60oC w/o NPX  
46.8 +/- 2.6 48.0 ± 3.6 49.7 ± 3.1 52.5 ± 2.1 
(81.8) (85.2) (89.5) (92.9) 
 4oC w/ NPX  
59.4 +/- 0.9 56.7 ± 2.1 59.5 ± 0.7 57.3 ± 0.6 
(104.0) (100.6) (107.2) (101.5) 
 60oC w/ NPX  
51.3 +/- 4.3 52.7 ± 1.4 49.7 ± 2.5 50.5 ± 0.7 
(89.7) (93.5) (89.5) (89.4) 
 
Figure 33. Helicity after pasteurization in the absence and presence of naproxen. Samples held at 
4oC in the absence of NPX were treated as controls and set to 100% helicity (---). All other 
values were calculated against these controls.   
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A significant amount of helicity was lost upon pasteurization of BSA species without 
ligand bound. Ligand binding capabilities of these samples was determined using NPX to probe 
the high affinity site DS2. 
Prior to pasteurization, all samples were able to tightly bind NPX with Ka values in the 
range of 107 M-1 which correspond well with published values (Figure 34). After pasteurization, 
these values decreased by several fold for all species of BSA except BSAx-123t-PEG8. This 
suggests major structural changes that greatly affect DS2.  
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Conclusions 
 Attachment of a PEG chain to BSA clearly affected the thermal stability of the protein. 
PEGylation, while lowering Tm, increased Tagg. Use of a short activating agent resulted in 
alteration of the surface of BSA due to interaction with the hydrophobic DIBO group, resulting 
in a marked decrease in Tm. Added space between the protein surface and the DIBO group 
lessened the effect of the nonpolar DIBO. 
Mal-PEG8 attached at the lone free thiol of BSA showed an increase in Tagg but peak 
broadening may be due to the dissolution of the thioether linker. Both BSAx-123t-PEG8 and 
BSAx-PEG4-123t-PEG8 effectively blocked aggregation, as seen by considerably higher Tagg. 
 PEGylation and pre-loading of complexes with a high affinity ligand are insufficient 
measures for maintenance of helicity during pasteurization. Sterilization of PEG species in the 
absence of ligand resulted in significant loss of helicity along with reduction of ligand binding 
capabilities. Pre-loading PEGylated BSA species mitigated these losses but still resulted in some 
loss of helicity. A combination of effects is needed to stabilize the complex. Binding NPX prior 
to pasteurization helps to prevent denaturation while PEGylation if more effective at preventing 
aggregation. 
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CHAPTER VI 
GENERAL CONCLUSIONS AND FUTURE RESEARCH 
General Conclusions 
Three different species of PEGylated BSA have been developed using thiol-maleimide and 
strain-promoted azide-alkyne cycloaddition “click” chemistries. All three products were mixtures 
of predominantly BSA2-4-R-PEG8 with some amount of unmodified BSA and higher molecular 
weight species. BSAx-PEG4-123t-PEG8 was the most homogeneous sample, containing the 
fewest higher molecular weight species while BSAx-te-PEG8 was the least homogeneous, 
containing a large number of higher molecular weight species. The wider distribution of BSAx-
te-PEG8 was unexpected due to the presence of a single PEGylation site at Cys34. Formation of 
higher molecular weight species was attributed to the side-reaction of Mal-PEG8 with native 
lysines. 
 All species of BSAx-R-PEG8 demonstrated similar ligand binding capabilities. DS2 was 
unaffected as association constants for naproxen were within the range of reported values for 
unmodified BSA. Interactions between DS1 and sulfamethoxazole, however, were greatly 
weakened by PEGylation. While the number of binding sites for each remained in agreement 
with the literature, association constants were several times smaller for PEGylated BSA than 
unmodified FAF-BSA.  
The difference in effects of PEGylation on these binding sites was likely due to the 
placement of the PEG backbone. In the case of BSAx-te-PEG8, the main site of modification was  
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Cys34 in Domain IA. DS1 is located at the interface of Domains IB and IIA. Conformational 
changes due to PEGylation in the same domain altered the cavity of DS1 and greatly reduced 
binding capabilities. DS2, on the other hand, is located in Domain IIIA. Modifications made at 
Cys34 appear to have little to no effect on ligand binding to DS2. 
For BSAx-123t-PEG8 and BSAx-PEG4-123t-PEG8, the exact site of modification is 
unknown as both activating agents were attached by an NHS-lysine reaction. BSA contains 59 
lysines. 20 appear in Domains I and III while 19 are found in Domain II. Given the high number 
and even distribution of potential sites of modification, a preference for a given domain is not 
readily apparent. However, similar drug binding profiles between BSAx-te-PEG8 and BSAx-R-
123t-PEG8 of this study suggest a preference for modification of Domain I. 
Temperature of unfolding was most affected by activation with the short DIBO-NHS. 
Both BSAx-te-PEG8 and BSAx-PEG4-123t-PEG8 showed similar denaturation curves to 
unmodified FAF-BSA. BSAx-123t-PEG8 was the least thermally stable of the complexes. This 
was attributed to the proximity of the hydrophobic DIBO group to the surface of BSA altering 
solvent interaction. Moving the DIBO further from the protein surface, as in BSAx-PEG4-123t-
PEG8, or complete elimination of DIBO (BSAx-te-PEG8), restored Tm to similar values for that 
of unmodified FAF-BSA. 
 The reverse was found for the temperature of aggregation. BSAx-R-123t-PEG8 species 
aggregated at much higher temperatures than either FAF-BSA or BSAx-te-PEG8. While Cys34 
modified FAF-BSA had a higher Tagg, the signal began increasing at a much lower temperature 
than FAF-BSA, likely due to the dissolution of the thioether linker. This instability was 
potentially due to the high concentration of excess thiol from 2-Mercaptoethanol in the 
denaturing buffer. 
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PEGylation and pre-loading of a high affinity DS2 ligand proved insufficient to allow for 
omission of stabilizing agents used in the pasteurization process. A significant decrease in 
helicity was seen for all PEGylated BSA species following pasteurization in the absence of 
naproxen. When sterilized with naproxen bound, a moderate loss of helicity was seen for all 
species of BSA. A combination of PEGylation and pre-loading the complex with a tightly bound 
ligand reduced the denaturing effects of pasteurization but did not completely eliminate them. 
Future Research 
The future of this project may be aimed at answering four questions: 1) Can a 
homogeneous BSAx-R-PEG8 product be generated with higher yields? 2) Can a fatty acid which 
does not compete for DS2 be substituted for caprylate? 3) Can these PEGylated species 
effectively release drugs? and 4) Does PEGylation affect cellular uptake? 
 The formation of three different forms of PEGylated BSA has been verified but the 
production process may still be improved. Yields and homogeneity of the products are 
potentially tied to the distance between BSA and the PEG8 backbone. An additional 14 Å 
between BSA and PEG8 was gained by incorporation of a PEG4 linker into the activating agent. 
This modification produced slightly higher yields and a more homogeneous final product. 
Extension of the PEG arms is the easiest way to increase this distance. The largest available 
eight-armed PEG is 40 kDa, each branch having an average molecular weight of 5 kDa which 
corresponds to 113 subunits. By extending these branches, the congestion around the PEG 
backbone will be relieved. Less steric hindrance would allow for BSA molecules to have easier 
access to the terminal functional groups. The amount of PEGylated product generated would 
increase while the number of different species formed would decrease. 
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 Caprylate, one of the stabilizing agents used in pasteurization, is a saturated eight-carbon 
fatty acid (8:0) with an affinity for DS2 (Kawai et al., 2017). Oleate (18:1), palmitate (16:0), and 
linoleate (18:2) account for the majority of bound fatty acids to human serum albumin (A. Saifer 
& Goldman, 1961). One of these compounds may prove to be an alternative stabilizing agent. 
 BSA contains seven fatty acid binding sites (Bhattacharya, Grüne & Curry, 2000; 
Rizzuti, Bartucci, Sportelli & Guzzi, 2015; Simard et al., 2005). Fatty acid site 5 (FA5) resides in 
Domain III and contains hydrophilic features (Y400 and K524) at the entrance to the cavity 
which interact with the polar head group of bound fatty acids. This cavity has been shown to 
bind long chain fatty acids with the highest affinity of the seven sites (Rizzuti et al., 2015; 
Simard et al., 2005). 
 DS2 of BSA is also located in Domain III with polar residues at Y410, R409, and S488. 
Use of a single long chain fatty acid which preferentially binds to FA5 may provide a substitute 
for caprylate in the pasteurization process. This would reduce competition for DS2, however, the 
proximity of FA5 to DS2 may alter binding profiles. By binding to a site away from DS2, 
thermal stability may be enhanced while maintaining ligand binding capabilities. 
 Also of interest is the ability to release bound drugs. Reported results show that these 
PEGylated BSA species are able to bind ligands, if only in DS2. If addition of a DS2 ligand is 
required before sterilization, the storage stability of the drug-BSA complex must be evaluated to 
avoid dissociation of the complex before administration. Diffusion-based experiments 
monitoring the effects of pH, temperature, time, etc. will provide information as to the shelf-life 
of these formulated products. 
 Gp60 has been identified as a cell surface receptor for albumin and plays a key role in the 
efficacy of the non-PEGylated albumin-based therapy Abraxane® (Desai, 2008; Schnitzer, 1992). 
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Albumin-based nanoparticles prepared via conjugation of BSA with either polystyrene (Wang, 
Tiruppathi, Cho, Minshall & Malik, 2011) or PEGylated liposomes (Thöle, Nobmann, Huwyler, 
Bartmann & Fricker, 2002) were successfully endocytosed into cells in vitro. This suggests that 
the degree of PEGylation in BSAx-te-PEG8, BSAx-123t-PEG8, and BSAx-PEG4-123t-PEG8 will 
not necessarily inhibit gp60-mediated transcytosis. In order to evaluate the viability as drug 
delivery systems, the ability of cells to endocytose these PEGylated complexes must be assessed. 
These PEGylated species utilize more cost-effective components, require no specialized 
equipment, and modify the albumin core at a bare minimum of sites. By maintaining albumin 
close to its native form while conferring the benefits of PEGylation, potential alternatives to 
current drug delivery systems and protein-based therapies have been developed. 
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